<SEC-DOCUMENT>0001564590-19-042608.txt : 20191112
<SEC-HEADER>0001564590-19-042608.hdr.sgml : 20191112
<ACCEPTANCE-DATETIME>20191112081619
ACCESSION NUMBER:		0001564590-19-042608
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		17
CONFORMED PERIOD OF REPORT:	20191111
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20191112
DATE AS OF CHANGE:		20191112

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			FIBROGEN INC
		CENTRAL INDEX KEY:			0000921299
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36740
		FILM NUMBER:		191206302

	BUSINESS ADDRESS:	
		STREET 1:		409 ILLINOIS STREET
		CITY:			SAN FRANCISCO
		STATE:			CA
		ZIP:			94158
		BUSINESS PHONE:		415-978-1200

	MAIL ADDRESS:	
		STREET 1:		409 ILLINOIS STREET
		CITY:			SAN FRANCISCO
		STATE:			CA
		ZIP:			94158
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>fgen-8k_20191111.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml  version="1.0" encoding="utf-8"?>
<!-- DFIN ActiveDisclosure(SM) Inline XBRL Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date      : 2019-11-12T07:19:42.7214982+00:00 -->
<!-- Version            : 5.0.0.208 -->
<!-- Package ID         : 341f72577fb545b38573953bec11aa7b -->
<!-- Copyright (c) 2019 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<html xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:fgen="http://www.fibrogen.com/20191111" xmlns:us-types="http://fasb.org/us-types/2019-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2019-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2018-01-31" xmlns:srt-types="http://fasb.org/srt-types/2019-01-31" xmlns:srt="http://fasb.org/srt/2019-01-31" xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31" xmlns:naics="http://xbrl.sec.gov/naics/2017-01-31" xmlns:invest="http://xbrl.sec.gov/invest/2013-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2019-01-31" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2019-01-31" xmlns:country="http://xbrl.sec.gov/country/2017-01-31" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns="http://www.w3.org/1999/xhtml">
<head>
<meta http-equiv="Content-Type" content="text/html" />
<title>
fgen-8k_20191111.htm
</title>
</head>
<!-- NG Converter v5.0.19273.161 -->
<body><div style="display:none">
	<ix:header>
		<ix:hidden>
			<ix:nonNumeric id="F_000001" name="dei:AmendmentFlag" contextRef="C_0000921299_20191111_20191111">false</ix:nonNumeric>
			<ix:nonNumeric id="F_000003" name="dei:EntityRegistrantName" contextRef="C_0000921299_20191111_20191111">FIBROGEN INC</ix:nonNumeric>
			<ix:nonNumeric id="F_000004" name="dei:EntityCentralIndexKey" contextRef="C_0000921299_20191111_20191111">0000921299</ix:nonNumeric>
		</ix:hidden>
		<ix:references>
			<link:schemaRef xlink:type="simple" xlink:href="fgen-20191111.xsd" xlink:arcrole="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase"></link:schemaRef>
		</ix:references>
		<ix:resources>
			<xbrli:context id="C_0000921299_20191111_20191111">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-11-11</xbrli:startDate>
					<xbrli:endDate>2019-11-11</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
		</ix:resources>
	</ix:header>
</div>

<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="border-bottom:Solid 0.75pt;padding-bottom:0pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:2pt;border-bottom:Solid 0.75pt;padding-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="text-align:center;margin-top:4pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:18pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">UNITED STATES</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:18pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">SECURITIES AND EXCHANGE COMMISSION</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Washington, D.C. 20549</p>
<p style="text-align:center;margin-bottom:2pt;border-bottom:Solid 0.75pt;padding-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-top:15pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:18pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">FORM <ix:nonNumeric id="F_000000" name="dei:DocumentType" contextRef="C_0000921299_20191111_20191111">8-K</ix:nonNumeric></p>
<p style="text-align:center;margin-bottom:2pt;border-bottom:Solid 0.75pt;padding-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-top:13pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">CURRENT REPORT</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to Section&#160;13 or 15(d) of the Securities Exchange Act of 1934</p>
<p style="text-align:center;margin-top:13pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Date of Report (Date of earliest event reported): <ix:nonNumeric id="F_000002" name="dei:DocumentPeriodEndDate" contextRef="C_0000921299_20191111_20191111" format="ixt:datemonthdayyearen">November 11, 2019</ix:nonNumeric></p>
<p style="text-align:center;margin-bottom:2pt;border-bottom:Solid 0.75pt;padding-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:24pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">FibroGen, Inc.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Exact name of registrant as specified in its charter)</p>
<p style="text-align:center;margin-bottom:2pt;border-bottom:Solid 0.75pt;padding-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:539.85pt;;">
<tr>
<td style="width:170.95pt;"></td>
<td style="width:4.5pt;"></td>
<td style="width:186.3pt;"></td>
<td style="width:5.35pt;"></td>
<td style="width:172.75pt;"></td>
</tr>
<tr style="height:12.4pt;">
<td valign="top">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000007" name="dei:EntityIncorporationStateCountryCode" contextRef="C_0000921299_20191111_20191111" format="ixt-sec:stateprovnameen">Delaware</ix:nonNumeric></p></td>
<td valign="top">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="top">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000006" name="dei:EntityFileNumber" contextRef="C_0000921299_20191111_20191111">001-36740</ix:nonNumeric></p></td>
<td valign="top">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="top">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000008" name="dei:EntityTaxIdentificationNumber" contextRef="C_0000921299_20191111_20191111">77-0357827</ix:nonNumeric></p></td>
</tr>
<tr style="height:20.9pt;">
<td valign="top">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(State or other jurisdiction</p>
<p style="text-align:center;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">of incorporation)</p></td>
<td valign="top">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="top">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Commission</p>
<p style="text-align:center;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">File Number)</p></td>
<td valign="top">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="top">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(IRS Employer</p>
<p style="text-align:center;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Identification No.)</p></td>
</tr>
</table></div>
<p style="text-align:center;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">FibroGen, Inc.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000009" name="dei:EntityAddressAddressLine1" contextRef="C_0000921299_20191111_20191111">409 Illinois Street</ix:nonNumeric></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000010" name="dei:EntityAddressCityOrTown" contextRef="C_0000921299_20191111_20191111">San Francisco</ix:nonNumeric>, <ix:nonNumeric id="F_000011" name="dei:EntityAddressStateOrProvince" contextRef="C_0000921299_20191111_20191111">CA</ix:nonNumeric> <ix:nonNumeric id="F_000012" name="dei:EntityAddressPostalZipCode" contextRef="C_0000921299_20191111_20191111">94158</ix:nonNumeric></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Address of principal executive offices, including zip code)</p>
<p style="text-align:center;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonNumeric id="F_000013" name="dei:CityAreaCode" contextRef="C_0000921299_20191111_20191111">415</ix:nonNumeric>) <ix:nonNumeric id="F_000014" name="dei:LocalPhoneNumber" contextRef="C_0000921299_20191111_20191111">978-1200</ix:nonNumeric></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Registrant&#8217;s telephone number, including area code)</p>
<p style="text-align:center;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Not Applicable</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Former name or former address, if changed since last report.)</p>
<p style="text-align:center;margin-bottom:2pt;border-bottom:Solid 0.75pt;padding-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-top:13pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:3pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr style="height:12.4pt;">
<td valign="top" style="width:4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Segoe UI Symbol;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000015" name="dei:WrittenCommunications" contextRef="C_0000921299_20191111_20191111" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></p></td>
<td valign="bottom" style="width:96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</p></td>
</tr>
<tr style="height:12.4pt;">
<td valign="top" style="width:4%;">
<p style="margin-top:3pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Segoe UI Symbol;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000016" name="dei:SolicitingMaterial" contextRef="C_0000921299_20191111_20191111" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></p></td>
<td valign="bottom" style="width:96%;">
<p style="margin-top:3pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</p></td>
</tr>
<tr style="height:12.4pt;">
<td valign="top" style="width:4%;">
<p style="margin-top:3pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Segoe UI Symbol;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000017" name="dei:PreCommencementTenderOffer" contextRef="C_0000921299_20191111_20191111" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></p></td>
<td valign="bottom" style="width:96%;">
<p style="margin-top:3pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pre-commencement communications pursuant to Rule&#160;14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</p></td>
</tr>
<tr style="height:12.4pt;">
<td valign="top" style="width:4%;">
<p style="margin-top:3pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Segoe UI Symbol;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000018" name="dei:PreCommencementIssuerTenderOffer" contextRef="C_0000921299_20191111_20191111" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></p></td>
<td valign="bottom" style="width:96%;">
<p style="margin-top:3pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pre-commencement communications pursuant to Rule&#160;13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Securities registered pursuant to Section 12(b) of the Act:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-weight:bold;;font-size:8pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse;  margin-left:3.5%;width:90.83%;">
<tr>
<td style="width:28.83%;"></td>
<td style="width:34%;"></td>
<td style="width:28%;"></td>
</tr>
<tr>
<td valign="top" style=" border-top:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Title of each class</p></td>
<td valign="top" style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Trading Symbol</p></td>
<td valign="top" style=" border-top:solid 0.75pt #000000; border-right:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Name of each exchange on which registered</p></td>
</tr>
<tr>
<td valign="top" style=" border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-top:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000019" name="dei:Security12bTitle" contextRef="C_0000921299_20191111_20191111">Common Stock, $0.01 par value</ix:nonNumeric></p></td>
<td valign="top" style=" border-bottom:solid 0.75pt #000000; border-top:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000020" name="dei:TradingSymbol" contextRef="C_0000921299_20191111_20191111">FGEN</ix:nonNumeric></p></td>
<td valign="top" style=" border-bottom:solid 0.75pt #000000; border-right:solid 0.75pt #000000; border-top:solid 0.75pt #000000; border-left:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000021" name="dei:SecurityExchangeName" contextRef="C_0000921299_20191111_20191111" format="ixt-sec:exchnameen">The Nasdaq Global Select Market</ix:nonNumeric></p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:23.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Emerging growth company</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><span style="font-family:Segoe UI Symbol;"><ix:nonNumeric id="F_000005" name="dei:EntityEmergingGrowthCompany" contextRef="C_0000921299_20191111_20191111" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.<span style="margin-left:36pt;"></span><span style="font-family:Segoe UI Symbol;">&#9744;</span></p>
<p style="margin-bottom:2pt;border-bottom:Solid 0.75pt;padding-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;<br /></p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:2pt;">&#160;</p>
<p style="border-top:Solid 0.75pt #7F0000;padding-top:0pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:2pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:2pt;" id="part_1_2_1">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:424.3pt;;">
<tr>
<td style="width:43.2pt;"></td>
<td style="width:381.1pt;"></td>
</tr>
<tr style="height:12.4pt;">
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;2.02</p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:10.8pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Results of Operations and Financial Condition.</p></td>
</tr>
</table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On November 11, 2019, FibroGen, Inc. (&#8220;FibroGen&#8221;) issued a press release announcing financial results for the quarter ended September 30, 2019, and conducted an investor conference call to discuss financial results and provide a business update.&#160;A copy of such press release is furnished as Exhibit&#160;99.1 to this report and is incorporated herein by reference. An approximate transcript of the investor conference call is furnished as Exhibit 99.2 to this report.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The information in this Item&#160;2.02, including Exhibit&#160;99.1 and Exhibit 99.2, shall not be deemed &#8220;filed&#8221; for purposes of Section&#160;18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section&#160;or Sections&#160;11 and 12(a)(2)&#160;of the Securities Act of 1933, as amended. The information contained in this Item&#160;2.02, in Exhibit&#160;99.1 and in Exhibit 99.2 shall not be incorporated by reference into any filing with the U.S. Securities and Exchange Commission made by FibroGen, whether made before or after the date hereof, regardless of any general incorporation language in such filing.</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:395.9pt;;">
<tr>
<td style="width:43.2pt;"></td>
<td style="width:352.7pt;"></td>
</tr>
<tr style="height:12.4pt;">
<td valign="top">
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;" id="part_1_2_2">Item&#160;9.01</p></td>
<td valign="top">
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:10.8pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Financial Statements and Exhibits.</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:2.17%;"></td>
<td style="width:6.81%;"></td>
<td style="width:6.59%;"></td>
<td style="width:43.77%;"></td>
<td style="width:40.66%;"></td>
</tr>
<tr style="height:12.4pt;">
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(d)</p></td>
<td colspan="3" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:10.8pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exhibits</p></td>
<td style="border:none;padding:0;"></td>
</tr>
<tr style="height:3.3pt;">
<td colspan="2" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr style="height:12.15pt;">
<td colspan="2" valign="bottom">
<p style="text-align:center;margin-top:18pt;border-bottom:Solid 0.75pt;padding-bottom:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit&#160;No.</p></td>
<td valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td colspan="2" valign="bottom">
<p style="border-bottom:Solid 0.75pt;padding-bottom:0pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Description</p></td>
</tr>
<tr style="height:3.3pt;">
<td colspan="2" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="3" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr style="height:24.75pt;">
<td colspan="2" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">99.1</p></td>
<td valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td colspan="2" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="fgen-ex991_6.htm"><span style="text-decoration:underline;">Press Release titled &#8220;FibroGen Reports Third Quarter 2019 Financial Results,&#8221; dated November 11, 2019</span></a></p></td>
</tr>
<tr style="height:24.75pt;">
<td colspan="2" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">99.2</p></td>
<td valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td colspan="2" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="fgen-ex992_142.htm"><span style="text-decoration:underline;">Transcript of the Investor Conference Call, dated November 11, 2019</span></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
</tr>
<tr style="height:24.75pt;">
<td colspan="2" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">104</p></td>
<td valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td colspan="2" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cover Page Interactive Data File (embedded within the Inline XBRL document)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br /></p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:2pt;">&#160;</p>
<p style="border-top:Solid 0.75pt #7F0000;padding-top:0pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:2pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;" id="part_1_2_3">SIGNATURES</p>
<p style="margin-top:13pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:45.58%;"></td>
<td style="width:0.99%;"></td>
<td style="width:3.95%;"></td>
<td style="width:0.37%;"></td>
<td style="width:2.86%;"></td>
<td style="width:1.63%;"></td>
<td style="width:44.61%;"></td>
</tr>
<tr style="height:3.3pt;">
<td valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr style="height:12.4pt;">
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="3" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">F<span style="font-size:9pt;">IBRO</span>G<span style="font-size:9pt;">EN</span>, I<span style="font-size:9pt;">NC</span>.</p></td>
</tr>
<tr style="height:3.3pt;">
<td valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="4" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr style="height:12.4pt;">
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Dated: November 12, 2019</p></td>
<td valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="3" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr style="height:3.3pt;">
<td valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr style="height:15.45pt;">
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom">
<p style="margin-bottom:1pt;border-bottom:Solid 0.75pt;padding-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Pat Cotroneo</p></td>
</tr>
<tr style="height:12.4pt;">
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pat Cotroneo</p></td>
</tr>
<tr style="height:12.4pt;">
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Senior Vice President, Finance and Chief Financial Officer</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:2pt;">&#160;</p></body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>fgen-ex991_6.htm
<DESCRIPTION>EX-99.1
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
fgen-ex991_6.htm
</title>
</head>
<!-- NG Converter v5.0.19273.161 -->
<body>

<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:5.45%;text-indent:-5.45%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 99.1</p>
<p style="text-align:center;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">FibroGen Reports Third Quarter 2019 Financial Results</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:7.27%;margin-right:2.22%;text-indent:0%;font-weight:bold;;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.64%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.64%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="font-weight:bold;font-style:italic;">Roxadustat Positive Pooled Phase 3 Efficacy and Cardiovascular Safety Data Presented Last Friday at American Society of Nephrology 2019 Kidney Week</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.64%;white-space:nowrap">
<p style="margin-top:0pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.64%;white-space:nowrap">
<p style="margin-top:0pt;margin-bottom:0pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</font></p></td>
<td valign="top">
<p style="margin-top:0pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="font-weight:bold;font-style:italic;">Plan to Submit Roxadustat U.S. NDA This Quarter</font></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;margin-right:2.22%;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Conference Call Today at 5:00 p.m. Eastern Time/2:00 p.m. Pacific Time</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">SAN FRANCISCO, Nov. 11, 2019 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today reported financial results for the third quarter of 2019 and provided an update on the company&#8217;s recent developments.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;The FibroGen team achieved many milestones over the past few months, culminating with the positive Phase 3 results for roxadustat reported at the American Society of Nephrology conference last week in Washington, D.C.,&#8221; said Jim Schoeneck, Interim Chief Executive Officer, FibroGen. &#8220;This set of global studies covered the spectrum of chronic kidney disease anemia and is believed to be the largest and most comprehensive ever reported. We expect the positive cardiovascular safety data, comparing roxadustat to placebo in non-dialysis patients and to epoetin alfa in patients on dialysis, along with the superior efficacy results, can serve as the basis for regulatory approval in the U.S. and other jurisdictions. We plan to submit an NDA in the U.S. by the end of this quarter for both dialysis and non-dialysis patients with our partner AstraZeneca, and an MAA in Europe by the end of first quarter 2020 by our partner Astellas, followed by submissions to other regulatory authorities.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;In addition, roxadustat is now approved for CKD patients with anemia in China and was approved in Japan for anemia in CKD patients on dialysis. Our other clinical programs advanced, as we initiated our roxadustat Phase 2 study to treat anemia in patients receiving chemotherapy and enrolled the first patients in our pamrevlumab Phase 3 programs for both idiopathic pulmonary fibrosis (ZEPHYRUS) and locally advanced pancreatic cancer (LAPIS).</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;These major accomplishments demonstrate our commitment to the vision set by FibroGen&#8217;s founder and long-time CEO and Chairman, Tom Neff. We mourn his unexpected passing and are grateful for his leadership and rare ability to recognize and advance scientific innovation.&#8221;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Recent Developments &#8211; Roxadustat</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Roxadustat is a novel, oral, first-in-class treatment for chronic kidney disease (CKD) patients with anemia, discovered by FibroGen and developed globally in conjunction with our partners AstraZeneca and Astellas. Groundbreaking science on the body&#8217;s oxygen-sensing mechanism and adaptation to hypoxia was awarded the 2019 Nobel Prize in Physiology or Medicine and serves as the foundation for the mechanism of action for roxadustat. Roxadustat increases hemoglobin by mimicking the body&#8217;s natural response to low oxygen. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">American Society of Nephrology Kidney Week Presentations &#8211; November 6-9, 2019</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.64%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">Clinical results presented from six roxadustat Phase 3 studies comprising over 8,000 anemia patients with chronic kidney disease, as well as pooled results for patients not on dialysis and on dialysis, including an incident dialysis subgroup</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.64%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Courier New;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.64%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Courier New;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Courier New;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">o</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Courier New;font-size:10pt;"><font style="font-style:italic;font-family:Times New Roman;">For additional data presented, please see our November 8, 2019 press release. Please also see our website for FibroGen&#8217;s ASN presentations</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:14.55%;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.64%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><a name="_AEIOULastRenderedPageBreakAEIOU2"></a><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-weight:bold;font-family:Times New Roman;">Cardiovascular Safety Confirmed: </font><font style="font-family:Times New Roman;">In both</font><font style="font-family:Times New Roman;"> non-dialysis dependent and dialysis dependent CKD anemia patients</font><font style="font-weight:bold;font-family:Times New Roman;">:</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.64%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Courier New;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.64%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Courier New;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Courier New;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">o</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Courier New;font-size:10pt;"><font style="font-weight:bold;font-family:Times New Roman;">Non-Dialysis Dependent (NDD)</font><font style="font-family:Times New Roman;"> (n=4270):</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.64%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';"><font style="font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';">&#9642;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">Risk of MACE, MACE+, and all-cause mortality in roxadustat patients was comparable to placebo based on a reference non-inferiority margin of 1.3 </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.64%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';"><font style="font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';">&#9642;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">NDD results are based on ITT long-term follow-up analysis method agreed with the FDA</font></p></td></tr></table></div>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:7.27%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gfo20dp4oa1x000001.jpg" title="" alt="" style="width:390px;height:246px;"></p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:21.82%;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.64%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Courier New;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.64%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Courier New;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Courier New;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">o</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Courier New;font-size:10pt;"><font style="font-weight:bold;font-family:Times New Roman;">Dialysis Dependent (DD) </font><font style="font-family:Times New Roman;">(n=3880):</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.64%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';"><font style="font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';">&#9642;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">Risk of MACE and all-cause mortality in roxadustat patients were not increased compared to the active comparator, epoetin alfa</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.64%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';"><font style="font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';">&#9642;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">Roxadustat patients had a 14% lower risk of MACE+ than epoetin alfa patients</font></p></td></tr></table></div>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:10.91%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gfo20dp4oa1x000002.jpg" title="" alt="" style="width:451px;height:233px;"></p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:21.82%;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.64%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Courier New;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.64%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Courier New;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Courier New;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">o</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Courier New;font-size:10pt;"><a name="_AEIOULastRenderedPageBreakAEIOU3"></a><font style="font-family:Courier New;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-family:Courier New;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-weight:bold;font-family:Times New Roman;">Incident Dialysis (ID) Subgroup</font><font style="font-family:Times New Roman;"> (n=1526): In the clinically important ID subgroup of patients, initiating dialysis within 4 months prior to randomization: </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.64%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';"><font style="font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';">&#9642;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">Roxadustat patients had a 30% lower risk of MACE than epoetin alfa</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.64%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';"><font style="font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';">&#9642;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">Roxadustat patients had a 34% lower risk of MACE+ than epoetin alfa</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.64%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';"><font style="font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';">&#9642;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">Roxadustat patients had a trend towards lower all-cause mortality compared to epoetin alfa</font></p></td></tr></table></div>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:7.27%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gfo20dp4oa1x000003.jpg" title="" alt="" style="width:378px;height:258px;"></p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:10.91%;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.64%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Courier New;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.64%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Courier New;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Courier New;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">o</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Courier New;font-size:10pt;"><font style="font-family:Times New Roman;">Endpoint definitions, using centrally adjudicated events:</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.64%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';"><font style="font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';">&#9642;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">Time to first Major Adverse Cardiovascular Events (MACE), a composite endpoint including all-cause mortality, myocardial infarction, and stroke</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.64%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';"><font style="font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';">&#9642;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">Time to first MACE+, referring to MACE plus unstable angina and heart failure requiring hospitalization</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.64%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';"><font style="font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';">&#9642;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">Time to all-cause mortality</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:21.82%;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.64%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-weight:bold;font-family:Times New Roman;">Primary Efficacy Endpoints Met in all Individual Studies and Pooled Analyses</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.64%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Courier New;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.64%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Courier New;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Courier New;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">o</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Courier New;font-size:10pt;"><font style="font-family:Times New Roman;">Met primary efficacy endpoint of mean change in hemoglobin (Hb) from baseline to average Hb weeks 28-52 in each of the six individual studies and in each of the two pooled efficacy analyses</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.64%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Courier New;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.64%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Courier New;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Courier New;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">o</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Courier New;font-size:10pt;"><font style="font-family:Times New Roman;">Statistically superior to placebo in the NDD pool </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.64%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Courier New;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.64%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Courier New;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Courier New;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">o</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Courier New;font-size:10pt;"><font style="font-family:Times New Roman;">Statistically superior to epoetin alfa in the DD pool</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:10.91%;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.64%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-weight:bold;font-family:Times New Roman;">Other Pooled Efficacy Analyses</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.64%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Courier New;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.64%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Courier New;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Courier New;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">o</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Courier New;font-size:10pt;"><font style="font-family:Times New Roman;">Non-Dialysis Dependent </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.64%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';"><font style="font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';">&#9642;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">In the pooled analysis, roxadustat was superior to placebo, with significantly larger Hb increase than placebo regardless of </font><font style="font-style:italic;font-family:Times New Roman;">iron-repletion</font><font style="font-family:Times New Roman;"> status at baseline </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.64%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';"><font style="font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';">&#9642;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">Roxadustat treatment reduced the need for </font><font style="font-style:italic;font-family:Times New Roman;">rescue treatment</font><font style="font-family:Times New Roman;"> and </font><font style="font-style:italic;font-family:Times New Roman;">red blood cell</font><font style="font-family:Times New Roman;"> </font><font style="font-style:italic;font-family:Times New Roman;">transfusion</font><font style="font-family:Times New Roman;"> (RBC)</font><font style="font-style:italic;font-family:Times New Roman;"> </font><font style="font-family:Times New Roman;">compared to placebo </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.64%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';"><font style="font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';">&#9642;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">Roxadustat slowed </font><font style="font-style:italic;font-family:Times New Roman;">the decline in renal function </font><font style="font-family:Times New Roman;">compared to placebo in patients eGFR &gt;= 15</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.64%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';"><font style="font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';">&#9642;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">Roxadustat reduced</font><font style="font-style:italic;font-family:Times New Roman;"> LDL cholesterol</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.64%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Courier New;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.64%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Courier New;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Courier New;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">o</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Courier New;font-size:10pt;"><font style="font-family:Times New Roman;">Dialysis Dependent </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.64%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';"><font style="font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';">&#9642;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">The larger Hb increase in patients treated with roxadustat vs. epoetin alfa was particularly notable in </font><font style="font-style:italic;font-family:Times New Roman;">patients with inflammation</font><font style="font-family:Times New Roman;"> (elevated CRP level) </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.64%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';"><font style="font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';">&#9642;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">Roxadustat treatment reduced the need for </font><font style="font-style:italic;font-family:Times New Roman;">RBC transfusion</font><font style="font-family:Times New Roman;"> compared to epoetin alfa</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.64%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';"><font style="font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';">&#9642;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">Less </font><font style="font-style:italic;font-family:Times New Roman;">IV iron</font><font style="font-family:Times New Roman;"> was required in patients receiving roxadustat versus patients receiving epoetin alfa</font><font style="font-weight:bold;font-family:Times New Roman;"> </font></p></td></tr></table></div>
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:10.91%;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU4"></a><font style="text-decoration:underline;">Other Recent Developments, Recognition and Futur</font><font style="text-decoration:underline;">e Milestones</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Roxadustat U.S. and EU Regulatory Timelines</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.64%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">Expect to submit U.S. NDA for roxadustat for the treatment of anemia in CKD patients both on dialysis and not on dialysis this quarter</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.64%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">Astellas expected to submit the Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) within the second half of their 2019 fiscal year, ending March 2020 </font></p></td></tr></table></div>
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:3.64%;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Roxadustat for Anemia in CKD &#8211; Approvals and Market Activity </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.64%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">Expanded approval of roxadustat (China tradename: &#29233;&#29790;&#21331;&#174;) in China to include the treatment of anemia in CKD patients who are not dialysis-dependent </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.64%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">Roxadustat (Japan tradename: Evrenzo&#174;) approved in Japan for the treatment of anemia associated with CKD in dialysis patients</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.64%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">First prescriptions written for roxadustat for patients in China </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.64%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">FibroGen booked commercial product revenue for the first time (China) </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.64%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">Roxadustat received the 2019 Dushu Lake Prize &#29420;&#22661;&#28246;&#26479; in China for &#8220;On-Market Innovative Drug with Highest Clinical Value&#8221;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.64%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">Results from the two China Phase 3 studies published in the </font><font style="font-style:italic;font-family:Times New Roman;">New England Journal of Medicine</font><font style="font-family:Times New Roman;"> (NEJM)</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:7.27%;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Development Programs</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:3.64%;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.64%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-weight:bold;font-family:Times New Roman;">Roxadustat for Anemia in Oncology</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.64%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Courier New;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.64%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Courier New;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Courier New;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">o</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Courier New;font-size:10pt;"><font style="font-family:Times New Roman;">Myelodysplastic Syndromes (MDS) </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.64%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';"><font style="font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';">&#9642;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">Clinical proof-of-concept study accepted for oral presentation at the 2019 American Society of Hematology Annual Meeting</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.64%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';"><font style="font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';">&#9642;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">Randomized placebo-controlled portion of global Phase 3 study ongoing</font><font style="font-weight:bold;font-family:Times New Roman;"> </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.64%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Courier New;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.64%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Courier New;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Courier New;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">o</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Courier New;font-size:10pt;"><font style="font-family:Times New Roman;">Chemotherapy-Induced Anemia (CIA) </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.64%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';"><font style="font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';">&#9642;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">Initiated patient dosing in Phase 2 study</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:25.45%;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.64%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-weight:bold;font-family:Times New Roman;">Pamrevlumab for Idiopathic Pulmonary Fibrosis (IPF) </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.64%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Courier New;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.64%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Courier New;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Courier New;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">o</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Courier New;font-size:10pt;"><font style="font-family:Times New Roman;">Initiated dosing in the pivotal ZEPHYRUS Phase 3 randomized, double-blind, placebo-controlled study</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:14.55%;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.64%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-weight:bold;font-family:Times New Roman;">Pamrevlumab for Locally Advanced Pancreatic Cancer (LAPC) </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.64%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Courier New;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.64%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Courier New;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Courier New;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">o</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Courier New;font-size:10pt;"><font style="font-family:Times New Roman;">Initiated dosing in the pivotal LAPIS Phase 3 randomized, double-blind, placebo-controlled study</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:14.55%;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.64%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-weight:bold;font-family:Times New Roman;">Pamrevlumab for Duchenne Muscular Dystrophy (DMD) </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.64%;white-space:nowrap">
<p style="margin-top:0pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Courier New;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.64%;white-space:nowrap">
<p style="margin-top:0pt;margin-bottom:0pt;font-family:Courier New;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Courier New;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">o</font></p></td>
<td valign="top">
<p style="margin-top:0pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Courier New;font-size:10pt;"><font style="font-family:Times New Roman;">Expect to meet with the FDA this quarter to discuss clinical development plan </font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-right:0.81%;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Corporate and Financial</font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.64%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">Net loss for the third quarter of 2019 was $49.4 million, or $0.57 net loss per basic and diluted share, compared to a net loss of $42.6 million, or $0.50 net loss per basic and diluted share one year ago</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.64%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">At September 30, 2019, FibroGen had $666.5 million in cash, restricted time deposits, cash equivalents, investments, and receivables </font></p></td></tr></table></div>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Conference Call and Webcast Details </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">FibroGen will host a conference call and webcast today, Monday, November 11, 2019, at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time) to discuss financial results and provide a business update. A live audio webcast of the call may be accessed in the investor section of the company&#8217;s website, www.fibrogen.com. To participate in the conference call by telephone, please dial 1 (888) 771-4371 (U.S. and Canada) or 1 (847) 585-4405 (international), reference the FibroGen third quarter 2019 financial results conference call, and use confirmation number 49132826. A replay of the webcast will be available shortly after the call for a period of four weeks. To access the replay, please dial 1 (888) 843-7419 (domestic) or 1 (630) 652-3042 (international), and use passcode <font style="font-weight:bold;">4132826.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">About Roxadustat</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Roxadustat (FG-4592) is a first-in-class, orally administered small molecule HIF-PH inhibitor that promotes erythropoiesis through increasing endogenous production of erythropoietin, improving iron regulation, and overcoming the negative impact of inflammation on hemoglobin syntheses and red blood cell production by downregulating hepcidin. Administration of roxadustat has been shown to induce coordinated erythropoiesis, increasing red blood cell count while maintaining plasma erythropoietin levels within or near normal physiologic range in multiple subpopulations of chronic kidney disease (CKD) patients, including in the presence of inflammation and without a need for supplemental intravenous iron. Roxadustat is currently approved in China for the treatment of anemia in CKD patients on dialysis and patients not on dialysis and approved in Japan for the treatment of anemia in CKD patients on dialysis. Roxadustat is in Phase 3 clinical development in the U.S. and Europe and in Phase 2/3 development in China for anemia associated with myelodysplastic syndromes (MDS), and in a Phase 2 U.S. trial for treatment of chemotherapy-induced anemia.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Astellas and FibroGen are collaborating on the development and commercialization of roxadustat for the treatment of anemia in territories including Japan, Europe, the Commonwealth of Independent States, the Middle East, and South Africa. AstraZeneca and FibroGen are collaborating on the development and commercialization of roxadustat for the treatment of anemia in the U.S., China, and other markets in the Americas and in Australia/New Zealand as well as Southeast Asia.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">About Pamrevlumab </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pamrevlumab is a first-in-class antibody developed by FibroGen to inhibit the activity of connective tissue growth factor (CTGF), a common factor in fibrotic and proliferative disorders characterized by persistent and excessive scarring that can lead to organ dysfunction and failure. Pamrevlumab is in Phase&#160;3 clinical development for the treatment of idiopathic pulmonary fibrosis (IPF) and for the treatment of locally advanced unresectable pancreatic cancer (LAPC), and in Phase 2 clinical development for the treatment of Duchenne muscular dystrophy (DMD). The U.S. Food and Drug Administration has granted Orphan Drug Designation to pamrevlumab for the treatment of patients with IPF, LAPC, and DMD. Pamrevlumab has also received Fast Track designation from the U.S. Food and Drug Administration for the treatment of patients with IPF and LAPC. Across all clinical studies, pamrevlumab has consistently demonstrated a good safety and tolerability profile to date. For information about pamrevlumab studies currently recruiting patients, please visit <font style="color:#auto;text-decoration:underline;">www.clinicaltrials.gov</font><font style="text-decoration:none;color:#auto;">.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU5"></a><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">About FibroGen </font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:normal;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">FibroGen, Inc., headquartered in San Francisco, California, with subsidiary offices in Beijing and Shanghai, People&#8217;s Republic of China, is a leading biopharmaceutical company discovering and developing a pipeline of first-in-class therapeutics. The company applies its pioneering expertise in hypoxia-inducible factor (HIF) and connective tissue growth factor (CTGF) biology, and clinical development to advance innovative medicines for the treatment of anemia, fibrotic disease, and cancer. Roxadustat, the company&#8217;s most advanced product, is an oral small molecule inhibitor of HIF prolyl hydroxylase (HIF-PH) activity, completing worldwide Phase 3 clinical development for the treatment of anemia in chronic kidney disease (CKD), is approved by the National Medical Products Administration (NMPA) in China for CKD patients on dialysis and not on dialysis and by the Ministry of Health, Labour and Welfare (MHLW) in Japan for CKD patients on dialysis. Roxadustat is in Phase 3 clinical development in the U.S. and Europe and in Phase 2/3 development in China for anemia associated with myelodysplastic syndromes (MDS), and in a Phase 2 U.S. trial for treatment of chemotherapy-induced anemia. Pamrevlumab, an anti-CTGF human monoclonal antibody, is in Phase 3 clinical development for the treatment of idiopathic pulmonary fibrosis (IPF) and pancreatic cancer, and is currently in a Phase 2 trial for Duchenne muscular dystrophy (DMD). FibroGen is also developing a biosynthetic cornea in China. For more information, please visit <font style="color:#auto;text-decoration:underline;">www.fibrogen.com</font>.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Forward-Looking Statements </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:normal;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">This release contains forward-looking statements regarding our strategy, future plans and prospects, including statements regarding the development of the company&#8217;s product candidates, the potential safety and efficacy profile of our product candidates, our interpretation of the pooled safety analyses and other analyses of the global Phase 3 program for roxadustat, the potential for our Phase 3 program data to form the basis of a regulatory approval, our clinical and regulatory plans, and those of our partners. These forward-looking statements include, but are not limited to, statements about our plans, objectives, representations and contentions and are not historical facts and typically are identified by use of terms such as &#8220;may,&#8221; &#8220;will&#8221;, &#8220;should,&#8221; &#8220;on track,&#8221; &#8220;could,&#8221; &#8220;expect,&#8221; &#8220;plan,&#8221; &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;estimate,&#8221; &#8220;predict,&#8221; &#8220;potential,&#8221; &#8220;continue&#8221; and similar words, although some forward-looking statements are expressed differently. Our actual results may differ materially from those indicated in these forward-looking statements due to risks and uncertainties related to the continued progress and timing of our various programs, including the enrollment and results from ongoing and potential future clinical trials, and other matters that are described in our Annual Report on Form 10-K for the fiscal year ended December 31, 2018 and our quarterly report on 10-Q for the fiscal quarter ended September 30, 2019 filed with the Securities and Exchange Commission (SEC), including the risk factors set forth therein. Investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release, and we undertake no obligation to update any forward-looking statement in this press release, except as required by law.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"># # #</p>
<p style="margin-bottom:10pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:10pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br /></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU6"></a><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Condensed Consolidated Balance Sheets</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(In thousands)</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:63.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.76%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">September&#160;30, 2019</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.06%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.76%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31, 2018 (1)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35.6%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Unaudited)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Assets</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.76%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.76%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Current assets:</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.76%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.76%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash and cash equivalents</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">196,592</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">89,258</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Short-term investments</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">432,040</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">532,144</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accounts receivable</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19,225</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">63,684</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Inventory</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,908</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:63.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prepaid expenses and other current assets</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">133,715</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.06%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,929</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total current assets</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">786,480</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">690,015</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.76%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.76%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Restricted time deposits</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,145</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,145</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Long-term investments</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,999</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">55,820</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment, net</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">43,208</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">127,198</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Finance lease right-of-use assets</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">42,064</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:63.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other assets</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,068</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.06%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,420</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:63.38%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Total assets</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">893,964</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.06%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">880,598</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.76%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.76%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Liabilities, stockholders&#8217; equity and non-controlling interests</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.76%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.76%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Current liabilities:</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.76%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.76%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accounts payable</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,055</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,139</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued and other liabilities</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">70,825</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">66,123</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred revenue</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">257</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,771</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:63.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Finance lease liabilities, current</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,149</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.06%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total current liabilities</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">87,286</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">89,033</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.76%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.76%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Long-term portion of lease obligations</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,242</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">97,157</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Product development obligations</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16,256</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16,798</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred rent</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,038</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred revenue, net of current</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">98,708</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">136,109</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Finance lease liabilities, non-current</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">40,713</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:63.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other long-term liabilities</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">36,041</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.06%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,993</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total liabilities</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">280,246</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">352,128</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.76%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.76%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total stockholders&#8217; equity</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">594,447</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">509,199</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:63.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Non-controlling interests</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19,271</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.06%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19,271</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:63.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total equity</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">613,718</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.06%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">528,470</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:63.38%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Total liabilities, stockholders&#8217; equity and non-controlling interests</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">893,964</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.06%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">880,598</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.64%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(1)</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="font-weight:normal;">The condensed consolidated balance sheet amounts at December&#160;31, 2018 are derived from audited financial statements.</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><br /></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU7"></a><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Condensed Consolidated Statements </font><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">of Operations</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(In thousands, except per share data)</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:45.54%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:25.7%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended September&#160;30,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.02%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:25.7%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Nine Months Ended September&#160;30,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:45.54%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.02%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="14" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.44%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Unaudited)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Revenue:</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">License revenue</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,935</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">162,517</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,323</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Development and other revenue</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20,660</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">29,027</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">85,507</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">90,580</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:45.54%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Product revenue</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">579</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.9%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.02%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">579</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.9%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total revenue</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">33,174</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">29,027</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">248,603</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">104,903</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Operating costs and expenses:</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cost of goods sold</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">242</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">242</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">49,963</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">56,443</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">152,467</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">165,555</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:45.54%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Selling, general and administrative</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">35,823</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.9%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,356</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.02%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">84,772</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.9%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">45,961</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:45.54%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total operating costs and expenses</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">86,028</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.9%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">71,799</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.02%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">237,481</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.9%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">211,516</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Income (loss) from operations</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(52,854</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(42,772</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,122</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(106,613</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Interest and other, net:</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest expense</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(702</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,739</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,209</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(8,257</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:45.54%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest income and other, net</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,193</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.9%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,079</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.02%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,496</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.9%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,796</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:45.54%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total interest and other, net</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,491</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.9%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">340</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.02%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,287</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.9%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(461</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Income (loss) before income taxes</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(49,363</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(42,432</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21,409</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(107,074</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:45.54%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Provision for income taxes</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">76</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.9%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">124</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.02%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">256</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.9%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">299</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:45.54%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Net income (loss)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(49,439</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.9%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(42,556</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.02%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21,153</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.9%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(107,373</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net income (loss) per share</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Basic</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.57</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.50</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.24</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1.28</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Diluted</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.57</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.50</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.23</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1.28</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted average number of common shares used to calculate net income (loss) per share:</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Basic</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">87,007</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">84,508</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">86,390</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">83,713</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Diluted</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">87,007</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">84,508</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">91,995</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">83,713</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"># # #</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Contact</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">FibroGen, Inc. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Michael Tung, M.D.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Investor Relations</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.415.978.1433</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#auto;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">ir@fibrogen.com</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.2
<SEQUENCE>3
<FILENAME>fgen-ex992_142.htm
<DESCRIPTION>EX-99.2
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
fgen-ex992_142.htm
</title>
</head>
<!-- NG Converter v5.0.19273.161 -->
<body>

<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 99.2</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Welcome to the FibroGen Third Quarter 2019 Financial Results Conference Call. My name is Erin and I'll be your operator for today's call. At this time, all participants are in a listen-only mode. Later, we will conduct a question-and-answer session. During the question-and-answer session, if you have a question, please press star, then 1 on your touchtone phone.&nbsp;&nbsp;Please note that this conference is being recorded.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">I will now turn the call over to Michael. Michael, you may begin.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Thank you, Erin, and good afternoon, everyone. Thank you for joining our call. Today, we'll be reporting financial results and corporate updates for the third quarter of 2019. Joining me today on the call are Jim Schoeneck, Interim Chief Executive Officer; Dr. Peony Yu, Chief Medical Officer; Ms. Chris Chung, Senior Vice President, China; Dr. Elias Kouchakji, Senior Vice President, Clinical Development, and Drug Safety and Pharmacovigilance; and Mr. Pat Cotroneo, Chief Financial Officer.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Following our prepared remarks, Jim will discuss upcoming milestones, and we will then open the call to Q&amp;A. During this call, we may make forward-looking statements regarding our business, including our collaborations with AstraZeneca and Astellas; financial guidance; the initiation, enrollment, design, conduct, and results of clinical trials; our regulatory strategies and potential regulatory results; our research and development activities; and certain other business matters.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For risks and uncertainties regarding our business and statements made on the call today, as well as factors beyond our control that may cause differences between current expectations and actual results, we refer you to our Annual Report on Form 10-K for the fiscal year ended December 31, 2018, and to our quarterly report on Form 10-Q for the quarter ended September 30, 2019, filed with the Securities and Exchange Commission. Copies of these filings may be found in the Investors section of our website.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We undertake no obligation to update any forward-looking statement, whether as a result of new information, future developments, or otherwise. The format for today's call includes remarks from FibroGen's management team and then we'll open the lines to take your questions. The press release reporting our financial results and business update and a webcast of today's conference call can be found on the Investors section of the FibroGen website at www.fibrogen.com.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The webcast will be available for 30 days from today's date. And with that, I'd now like to turn the call over to our Interim CEO, Jim Schoeneck.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">James A. Schoeneck</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;color:#212121;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Thank you Mike and thank you all for joining us today. During today<font style="color:#000000;">'</font>s call I will give<font style="color:#000000;"> you</font> an overview of our third quarter results and recent accomplishments. Dr. Peony Yu will then<font style="color:#000000;"> give a</font> review <font style="color:#000000;">of </font>the roxadustat data from the American Society of Nephrology meeting<font style="color:#000000;">,</font> which just wrapped up yesterday<font style="color:#000000;">. Following that</font> Chris Chung will update you on our China efforts. Dr. Elias <font style="color:#000000;">Kouchakji,</font> will give <font style="color:#000000;">us</font> a pamrevlumab update, and Pat Cotroneo will discuss our financials<font style="color:#000000;">.&nbsp;&nbsp;Then, </font>I&#8217;ll provide some closing comments and open the call to questions.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 99.2</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:0%;color:#212121;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU2"></a><font style="color:#212121;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">First I want to take a moment</font><font style="color:#212121;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> to acknowledge with a </font><font style="color:#000000;">great </font><font style="color:#212121;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">sense of loss, the recent and unexpected passing of FibroGen</font><font style="color:#000000;">'</font><font style="color:#212121;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">s </font><font style="color:#000000;">Founder</font><font style="color:#212121;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> and long term Chairman and CEO, Tom Neff.&nbsp;&nbsp;Tom was a man of vision, determination and leadership and was deeply committed to innovation. We at FibroGen are </font><font style="color:#212121;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">deeply indebted to him. Tom founded FibroGen in 1993 with the vision of treating fibrosis at a time when there was no hope for </font><font style="color:#000000;">the</font><font style="color:#212121;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> disease category. He led the company for over 25 years and established a culture and </font><font style="color:#000000;">a </font><font style="color:#212121;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">team driven to support his vision moti</font><font style="color:#212121;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">vated by his commitment to improve the lives of those suffering from conditions with no satisfactory therapeutic options. In founding FibroGen, Tom assembled global scientific leaders in areas critical to </font><font style="color:#000000;">the</font><font style="color:#212121;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> understanding of fibrosis and the fibrotic dise</font><font style="color:#212121;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ase mechanism</font><font style="color:#000000;">,</font><font style="color:#212121;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> ultimately providing the basis for pamrevlumab and through </font><font style="color:#000000;">the </font><font style="color:#212121;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">exploration of prolyl hydroxylase enzyme activity, the basis for roxadustat.</font><font style="color:#000000;"> Tom was intimately involved in the discovery and development of roxadustat and pamrevlumab, and posit</font><font style="color:#000000;">ion the company for great success given the breadth of the applications for both compounds.&nbsp;&nbsp;</font><font style="color:#212121;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">His contribution as a pioneer in the biotechnology industry will be measured by the lives </font><font style="color:#000000;">that </font><font style="color:#212121;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">he has and will continue to touch as FibroGen continues to develop m</font><font style="color:#212121;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">edicines for unmet medical needs. The FibroGen </font><font style="color:#000000;">Board</font><font style="color:#212121;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> and management team are committed to fulfill and build upon Tom</font><font style="color:#000000;">'</font><font style="color:#212121;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">s vision.</font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As you all saw, last month, the 2019 Nobel Prize in Physiology or Medicine was awarded to three physician scientists for their research into how cells sense oxygen, and how they function in low-oxygen conditions or hypoxia. The collective contributions of Dr. Bill Kaelin of the Dana-Farber Cancer Institute; Sir Peter Ratcliffe of the University of Oxford; and Dr. Gregg Semenza of Johns Hopkins University School of Medicine, identified the pathway by which cells detect oxygen and respond to hypoxia. This seminal science has paved the way for promising new strategies to fight anemia, cancer and many other diseases.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">FibroGen is fortunate to work closely with Bill Kaelin, a collaborator and member of the company's Scientific Advisory Board for nearly two decades. Today, roxadustat is the first medication in the world which applies this groundbreaking science. As Dr. Bob Provenzano stated at the American Society of Nephrology last week, this is a great example of cutting-edge science moving from bench to bedside. Roxadustat is already approved in China for the treatment of anemia associated with chronic kidney disease, and in Japan, for CKD patients on dialysis.&nbsp;&nbsp; We're also currently preparing regulatory submissions for the US and Europe.&nbsp;&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Last week, during the American Society of Nephrology Kidney Week 2019, FibroGen and our partners, Astellas and AstraZeneca, presented roxadustat data from our Phase 3 program as well as pooled cardiovascular safety and efficacy results.&nbsp;&nbsp;The pooled data kicked off ASN's High-Impact Clinical Trials session with a packed room of almost 2,000 people.&nbsp;&nbsp;One nephrologist called it the largest crowd for an anemia presentation in well over a decade.&nbsp;&nbsp;This set of global studies covered the spectrum of chronic kidney disease anemia and is believed to be the largest and most comprehensive study population ever reported with over 8,000 patients.&#160;Details of the data presented can be found on our website and in our press release from last Friday. Our studies assessed cardiovascular safety in dialysis- and non-dialysis-dependent patients using endpoints of Major Adverse Cardiovascular Events known as MACE, and MACE+, which adds hospitalization due to unstable angina and congestive heart failure.&nbsp;&nbsp;The pooled results showed that roxadustat's cardiovascular safety was comparable to placebo in non-dialysis-dependent patients and in dialysis-dependent patients roxadustat did not increase the risk of MACE and reduced the risk of MACE+ compared to epoetin alfa, the leading product currently used to treat anemia in this population.&nbsp;&nbsp;Finally, in the subgroup of dialysis patients who recently started dialysis, referred to as incident dialysis patients, roxadustat reduced risk of MACE by 30% and MACE+ by 34% compared to epoetin alfa. Roxadustat achieved the primary hemoglobin efficacy endpoint in all of these groups.&nbsp;&nbsp;Of note, roxadustat was shown to raise hemoglobin levels, regardless of iron status at baseline, in patients who required no supplementary IV iron, and in patients with inflammation, a group that is difficult to treat with current therapies.<font style="color:#000000;"> Having an oral product with this safety and efficacy profile can offer patients with</font> <font style="color:#000000;"> anemia of chronic kidney disease, and their doctors, a treatment unlike anything currently on the market in the US or Europe.&nbsp;&nbsp;</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 99.2</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU3"></a><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Let me briefly mention a few other highlights from the quarter. We initiated our Phase 3 pamrevlumab pro</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">grams, enrolling the first patients in our idiopathic pulmonary fibrosis or IPF trial as well as our study in locally advanced pancreatic cancer.&nbsp;&nbsp;Our Phase 2 IPF trial was published in The Lancet Respiratory Medicine journal and, in the company editorial </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Professor Athol Wells, of the Royal Brompton Hospital, stated: &#8220;In</font><font style="font-style:italic;"> conclusion, it</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">'</font><font style="font-style:italic;">s difficult to imagine more encouraging Phase 2 results of </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">a </font><font style="font-style:italic;">novel drug for IPF.</font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In China, we booked our first roxadustat product revenue anywhere in the world and we continue to prepare for the full market launch with our 50/50 partner AstraZeneca. In September, FibroGen and roxadustat won the 2019 Dushu Lake Prize for Innovative Drug with the Highest Clinical Value in China. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">I think you'll agree with me it's been a very, very accomplished quarter.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Now I<font style="color:#000000;">'</font>ll turn <font style="color:#000000;">it</font> over to Peony<font style="color:#000000;">, who will give you</font> a more in-depth discussion of roxadustat and the data from the ASN <font style="color:#000000;">meeting</font>.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">K. Peony Yu</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Thank you, Jim. Last week, FibroGen and our partners presented roxadustat Phase 3 results at the annual American Society of Nephrology meeting which included over 13,000 kidney professionals. All the nephrologists share our excitement of a potential game changer in anemia therapy based on strong scientific foundation. Today, I would like to review the highlights.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The pooled analysis included data from six Phase 3 trials which included over 8,000 patients and encompassed over 13,000 patient exposure years.&nbsp;&nbsp;</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our studies evaluated three patient populations, non-dialysis-dependent, dialysis-dependent and then incident dialysis, which is a subgroup of patients who recently started dialysis within four months of study participation. We've reported on results of the following safety endpoints: Major Adverse Cardiovascular Events or MACE endpoints consist of death due to all causes, non-fatal myocardial infarction, and non-fatal stroke. MACE + consists of the three MACE events, plus hospitalization due to heart failure or unstable angina.&nbsp;&nbsp;All-cause mortality is simply all deaths due to any cause. </p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To maintain objectivity and consistency the events in these cardiovascular endpoints were adjudicated by independent adjudicators blinded to treatment assignment.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The time to event analyses are conducted based on pooling strategy and analytical approaches agreed with the FDA and the time to MACE is the primary safety endpoint in the US, supported by results of MACE+, which is recognized as an important endpoint in the nephrology community. </p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In non-dialysis where roxadustat was compared to placebo, which is the gold standard in safety assessment, roxadustat was comparable to placebo in MACE and MACE+ risk, using a commonly applied non-inferiority margin of 1.3.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In dialysis patients, roxadustat reduced the risk of MACE+ by 14percent compared to epoetin alfa and had no increased risk of MACE compared to EPO using a commonly applied NI margin of 1.3.%. In incident dialysis roxadustat, had a 30% lower risk of MACE and a 34% lower risk of MACE+ than EPO.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 99.2</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU4"></a><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Let's discuss the rest of the efficacy and safety results, starting with non-dialysis.&nbsp;&nbsp;4,270 plus CKD patients were enrolled into the three Phase 3 non-dialysis studies comparing roxadustat to placebo. In these studies, we included </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CKD Stage 3, 4, and 5 patients, of which 42% were CKD Stage 5. Their anemia tends to be more severe with their more advanced chronic kidney disease and they have been generally excluded from prior large CKD anemia studies of ESAs.&nbsp;&nbsp;Similarly, we included p</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">atients with a range of iron stores with 40% of study patients non-iron replete at baseline and thus they were ineligible for ESA treatment based on the current ESA label.</font></p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Roxadustat met the primary efficacy endpoint of mean change from baseline to average hemoglobin over weeks 28 to 52 in which -- I'm sorry-- in each of the three individual Phase 3 studies and in the pool analyses in which roxadustat was superior to placebo regardless of CKD severity, regardless of severity of anemia at baseline, and regardless of iron repletion status.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Roxadustat&#8217;s efficacy is accompanied by an 81% risk reduction in use of rescue treatment, which includes IV iron, ESA, and transfusion, and a 74% reduction in the risk of red blood cell transfusion, with P-value point 001&nbsp;&nbsp;-- P-value less than. </p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Importantly in comparison to placebo, roxadustat patients also show a slower decline in eGFR which was a measure of kidney function. Patients were based in -- patients with baseline eGFR of 15 or higher during the first year of treatment.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The one year decline in eGFR in roxa patients was 2.8, which is significantly less than the decline in placebo patients of 4.4 with a treatment difference of 1.6 and has three zeroes in it. This represents a 38% reduction in eGFR decline relative to placebo.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Turning to cardiovascular safety, in the CKD non-dialysis pool, based on ITT analysis, roxadustat was comparable to placebo. For reference, here are the hazard ratios. MACE, hazard ratio of 1.08 with 95% confidence interval of 0.94 and 1.24., MACE+, hazard ratio of 1.04 with confidence interval of 0.91 and 1.18. </p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">All-cause mortality, hazard ratio of 1.06 with confidence interval of 0.91 and 1.23.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have received questions on the individual components of cardiovascular composite endpoint in non-dialysis, with the most interest in stroke, while this is most likely because of the TREAT study on darbepoetin that resulted in the ESA label restriction in its use in non-dialysis and dialysis patients. </p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">I want to be clear from the outset. We believe the data from the individual components of MACE and MACE+ in the roxadustat program are consistent with the results in the overall analysis. Stated another way, we believe the results in the individual components are comparable to placebo in non-dialysis. This is also true for the dialysis pool.&nbsp;&nbsp;</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Before we delve into details, I want to remind you that the roxadustat non-dialysis program was powered for assessing the MACE composite endpoint and not the individual components.&nbsp;&nbsp;To give a sense of magnitude in the roxadustat program stoke represents only 10% of the MACE events in the non-dialysis pool and the incidence of rate in roxadustat is comparable to placebo, which is 1.2 per 100 patient years in roxadustat versus 1.1 in placebo arm hazard ratio of 1.22, with 95% confidence interval of 0.80 and 1.86. As a reminder, in the TREAT study the incidence rate of stroke in darbepoetin was twice that of placebo, with hazard ratio of 1.92 and 95% confidence interval of 1.38 and 2.18.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The rest of the MACE+ components in our non-dialysis pool is as follows: all -cause mortality hazard ration of 1.06, confidence interval of 0.91 and 1.23, which we stated earlier.&nbsp;&nbsp;MI has a ratio of 1.28, confidence interval of 0.9 and 1.84. Unstable angina requiring hospitalization with hazard ratio a 0.49 and confidence interval of 0.19 and 1.27.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 99.2</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU5"></a><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Finally, congestive heart failure requiring hospitalization, which is an important &#8211; which is i</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">mportant in CKD patients -- has hazard ratio of 0.89, confidence interval of 0.72 and 1.12. Based on the composite endpoints of time -to MACE, MACE+, all -cause mortality and the individual components, the overall cardiovascular safety of roxadustat is com</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">parable to placebo. </font></p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The dialysis-dependent patient pool consists of 3,880 patients who were randomized 1:1 to receive roxadustat or epoetin alfa in three dialysis Phase 3 studies. The primary efficacy endpoint of mean change changing hemoglobin from baseline to week 28 to 52 was met in each individual study and in the pooled analyses. Roxadustat achieved higher hemoglobin level than active comparator of epoetin alfa. This result was seen in patients with or without inflammation as measured by CRP, with similar roxadustat dose requirements regardless of inflammation status, with roxadustat-treated patients receiving less IV iron than EPO patients, while transferrin saturation or TSAT, a measure of iron store in the body, were comparable between the two treatment arms.&nbsp;&nbsp;In addition, when compared with EPO, roxadustat-treated patients had a lower red blood cell transfusion risk than EPO-treated patients, hazard ratio of 0.82, p-value of 0.046. The combination of findings above reflects the benefits of coordinated erythropoiesis with roxadustat as resulted in more efficient iron utilization lower transfusion requirements and can potentially overcome ESA hypo-responsiveness. </p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Turning to cardiovascular endpoint analyses of the dialysis pool. In MACE and in all-cause mortality, roxadustat had no increase risk relative to EPO.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In MACE+, roxadustat had 14% reduction in risk compared to EPO. I would like to point out the incidence rate of each of the individual MACE+ components in dialysis are numerically lower in roxadustat than EPO.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Finally, let's talk about the exciting patient population incident dialysis, which is a sub-group of the dialysis-dependent pool.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Here we studied 1,526 new dialysis patients who commenced treatments within four months before study participation and were treated up to three years with an average treatment duration of 1.5 year. </p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the incident dialysis pool, in comparison to epoetin alfa, roxadustat treatment resulted in a 30% reduction in the risk of MACE and a 34% reduction in the risk of MACE+ with a trend for lower risk of death. These results suggest the potential long-term safety benefits in selecting roxadustat when initiating anemia therapy in dialysis patients.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To evaluate the merits of roxadustat, it is important to put together an overall picture, taking into account efficacy and safety, and ask, if this drug has the potential to improve anemia treatment in CKD patients.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our answer is yes. In non-dialysis, our Phase 3 program show roxadustat treatment corrected anemia effectively, regardless of iron repletion and reduce risk of rescue use of blood transfusion while also slowing down the decline in kidney function in patients with eGFR greater than or equal to 15 while MACE, MACE+ and all -cause mortality risk were comparable to placebo, the gold standard because of safety-related treatment restriction of ESA coupled with the iron repletion requirement and the inconvenience of parenteral administration requirement currently, there is little use of ESA in non-dialysis patients as US RDS reported that only 15% of patients entering dialysis had received prior ESA treatment.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If approved roxadustat could deliver the therapeutic benefits with the convenience of a pill unlike the ESA which requires frequent injection at the doctor's office. In addition to the favorable efficacy and safety characteristics, the convenient dosing of oral medication and removal of the financial and time burden from physicians need to stock and inject the medicine. We believe roxadustat has the potential to improve treatment access and patient compliance.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Therefore, we believe we have an unprecedented opportunity to expand anemia therapy to the millions of non-dialysis patients whose anemia goes unaddressed. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 99.2</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU6"></a><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In dialysis currently</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> the decision on the choice of anemia agent is generally made at the early periods of dialysis treatments. With a 30% reduction in MACE risk and a 34% reduction in MACE+ risk compared with epoetin alfa in incident dialysis patients, we believe roxadustat c</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ould be viewed as a safer option for patients initiating chronic dialysis, while benefiting from the robust efficacy in patients with or without inflammation with less IV iron use and lower transfusion rate compared to epoetin in the dialysis patients. </font></p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are privileged to have an opportunity to potentially introduce a new standard for anemia therapy for CKD patients with roxadustat, a first -in -class agent based on Nobel winning science.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We believe these compelling efficacy results with demonstration of clinical benefits accompanied by the above safety results could serve as a strong basis for marketing approval in both the US, Europe and other countries in the world.&nbsp;&nbsp;Working with our partner AstraZeneca, we have made substantial progress in preparing NDA for CKD anemia in patients on dialysis and in patients not on dialysis. We plan to submit the NDA for both indications before year end. We're working closely with Astellas, our European partner and then &#8211; and expect to file the MAA for both indications in the first quarter of 2020.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Encouraged by the safety and efficacy results in CKD, we continue to expand treatment of anemia for other etiologies.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In MDS we have two ongoing clinical studies, a Phase 3 US global study in transfusion -dependent MDS patients, and a Phase 2/3 study in non-transfusion -dependent MDS patients in China.&nbsp;&nbsp;From Phase 3 global study results of the open label lead-in portion demonstrating efficacy in MDS patients will be presented in an oral session of the upcoming American Society of Hematology meeting in Orlando next month. We have also started a Phase 2 US study of roxadustat for treating chemotherapy-induced anemia, which we believe to have much opportunity to address the unmet need of a large patient population. Our founding CEO led pioneering HIF-PHI for anemia therapy. We are committed to carry on Tom Neff&#8217;s legacy to develop innovative medicine to improve patient care.&nbsp;&nbsp;</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">I now like to turn the call over to Chris Chung.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Christine L. Chung</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Thanks, Peony. It has been an eventful quarter for us in China.&nbsp;&nbsp;Publication of data from the two China only Phase 3 studies in the New England Journal of Medicine was a landmark event, which was celebrated in China with much enthusiasm. The Chinese nephrology community envisions itself as leading the way internationally in the adoption of a transformative new paradigm for the treatment of anemia in CKD.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">With the expansion of the China label to include non-dialysis, our partnership with AstraZeneca is serving us well. We're able to leverage the significant commercialization capability and launch experience of what is now the largest multinational pharma in China with coverage at over 6,000 hospitals that represent the vast majority of the potential market for roxadustat. FibroGen in China has responsibility from medical affairs and we too have expanded our key opinion leader coverage and evidence generation activities over the last few years from the original 30. Phase 3 clinical trial sites to now over 300 leading hospitals and counting. As a joint team, we continue to advance our efforts in market development, distribution, reimbursement and gaining listings in hospitals.&nbsp;&nbsp;China, as the first launch market for roxadustat, has given us some very encouraging early signals about prescriber and patient receptivity, indicators which are helping us calibrate the scale and scope of our ambitions for the market.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 99.2</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU7"></a><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Looking at the different segments of the potential patient universe, in dialysis, the installed base of over 600,000 patients is now the single &#8211; </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the largest single country dialysis population of the world exceeding that of the United States. This is a substitution market for roxadustat. Treatment of anemia is well-established, but only one -fifth of patients are treated to the target hemoglobin of </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11. There continues to be double -digit growth in dialysis. After accounting for deaths, nearly 100,000 new patients come onto dialysis each year. They represent new candidates for roxadustat and many have no prior ESA experience. Within dialysis is approx</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">imately 100,000 patients or 14% who are treated on peritoneal dialysis, PD, instead of hemodialysis, HD.&nbsp;&nbsp;We believe the segment is particularly well -suited for an oral therapeutic like roxadustat because patients receive PD treatment at home.&nbsp;&nbsp;</font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Finally, the non-dialysis segment is even bigger in patient count, but ease-of-use is much less established. We believe as an oral therapy, roxadustat has the opportunity to greatly expand the addressable market.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We expect to know by the end of 2019, roxadustat will be included in the updated national reimbursement drug list or NRDL.&nbsp;&nbsp;Inclusion would be an important inflection point for the business as it would greatly increase patient affordability, accelerate hospital listing and expand overall market adoption.&nbsp;&nbsp; This remains a stretch goal as, historically, the NRDL cycles were farther apart in time and drugs were on the market for a few years before inclusion.&nbsp;&nbsp; In the event roxadustat is not admitted in this round, reimbursement would be a top priority for us in 2020.&nbsp;&nbsp;&nbsp;&nbsp;We look forward to keeping you updated on the exciting market opportunity in front of us in China.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">With this, I'll turn it over to Elias to discuss pamrevlumab. Elias Kouchakji</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Thank you, Chris, and good afternoon. I'd like to start with some introduction of pamrevlumab. It is a &#8211; the first in class fully human monoclonal antibody that inhibits the activity of connective tissue growth factor, also known as CTGF. It's a critical mediator of the progression of fibrosis and fibrotic diseases. Pamrevlumab is currently in Phase 3 clinical development for the treatment of both idiopathic pulmonary fibrosis or IPF, and unresectable locally -advanced pancreatic cancer also known as LAPC. Pamrevlumab is in Phase 2 for the treatment of Duchenne muscular dystrophy in non-ambulatory patients. These diseases share a commonality of fibrosis involvement and each represents an area of significant unmet medical need in which these patients face a dire prognosis.&nbsp;&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">I'd like to start with an update on IPF.&nbsp;&nbsp;In July we dosed the first patient in the ZEPHYRUS Phase 3 clinical study pf Pamrevlumab in patients with IPF. We continue to activate additional sites in this study and engage with our investigators to enroll patients. We are redoubling our efforts and improving our processes to bring sites online and expect an acceleration over the next few months. Our focus now is to activate sites with the expectation that enrollment will accelerate in the year 2020.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In September, as Jim mentioned, we announced The Lancet Respiratory Medicine publication of positive results from the company's PRAISE Phase 2 clinical study in IPF, showing both significant improvement in the primary efficacy endpoints of FVC change from baseline and reduction in disease progression and quantitative lung fibrosis as measured by HRCT or high resolution CT scan. This paper was well -received by the medical community at the 2019 European Respiratory Society International Congress. We are very appreciative of and encouraged by this reception. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In this publication, the authors reported that pamrevlumab demonstrated the potential for stabilization of disease, and for the first time in human studies, the potential of reversal of lung fibrosis in some patients. I'd like to remind to everyone that pamrevlumab has received Orphan Drug and Fast Track Designation from the FDA for the treatment of IPF.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 99.2</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU8"></a><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Moving to LAPC, our Phase 2 results showed the encouraging clinical evidence of the potential of pamrevlumab plus chemotherapy to transform unresectable LAPC patients</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> into patients who are eligible for surgical resection. We recently announced that the first patient was dosed in LAPIS our pivotal Phase 3 randomized double-blind placebo controlled study evaluating pamrevlumab as a neoadjuvant therapy for unresectable LA</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">PC patients. This study will enroll 260 patients, approximately, to receive chemotherapy of gemcitabine and nab-paclitaxel, and will be randomized to either pamrevlumab or placebo. </font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As you may know, this are very sick patient with limited options. With the primary endpoint of overall survival, at the end of the treatment period, we will be evaluating the rate of resection as a surrogate endpoint for a potential&nbsp;&nbsp;approval. Similar to IPF, pamrevlumab has received both Orphan Drug and Fast Track designation from the FDA for the treatment of this disease. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Turning to Duchenne muscular dystrophy, we will meet with the FDA this quarter to discuss the design of our pivotal Phase 3 program in DMD. We look forward to updating you in the future as this program advances. Also, we plan in the near future to publish additional data from patients who have completed one year of treatment in our Phase 2 study.&nbsp;&nbsp;Pamrevlumab has received Orphan Drug Designation from the FDA for the treatment of DMD.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In clinical studies in multiple indications, pamrevlumab has consistently shown positive efficacy results has demonstrated a good safety and tolerability profile. We are pleased to be progressing with the Phase 3 studies, to fulfill the vision of our late CEO Tom Neff whose goal in founding FibroGen was to treat fibrotic diseases. We look forward to updating you on the progress of the pamrevlumab program in the future.&nbsp;&nbsp; </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">I will turn over the call to our CFO Pat Cotroneo for the financial update. Pat?</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pat Cotroneo</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Thank you, Elias.&nbsp;&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As announced today, total revenue for the quarter ended September 30, 2019 was $33.2 million as compared to $29 million for the third quarter of 2018. For the same period operating costs and expenses were $86 million and net loss was $49.4 million or $0.57 per basic and diluted share as compared to operating costs and expenses of $71.8 million, and a net loss of $42.6 million or $0.50 per basic and diluted share for the third quarter last year. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Included in revenue for the quarter ended September 30, 2019 are first commercial sales of roxadustat drug product in China. The related net product revenue was $600,000 for the quarter.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Also included in operating costs and expenses for the quarter ended September 30, 2019 was an aggregate non-cash portion, totaling $19.6 million, of which $14.8 million was a result of stock-based compensation expense as compared to an aggregate non-cash portion of $16 million of which $14.3 million was a result of stock-based compensation expense for the same period in the prior year. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As stated in Q2 2019 in accordance with the US GAAP, we had included in our revenue recognition methodology a total of $180 million comprised of $50 million for an anticipated milestone from AstraZeneca relating to the filing of the US NDA and $130 million in anticipated milestones from Astellas in connection with the EU MAA filings, when such milestone achievements became probable.&nbsp;&nbsp;Included in our third quarter revenue recognition methodology is a $12.5 million milestone associated with the approval for CKD in dialysis patients in Japan.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The timing of when the payments related to these milestones will be remitted to FibroGen depends on when the milestones are actually achieved. As noted earlier on this call, our NDA submission is targeted for Q4 of this year and we expect the Astellas MAA submission to occur in the second half of the Astellas 2019 fiscal year, which ends March 31, 2020. Based on our latest forecasts, we estimate our 2019 ending cash to be in the range of $650 million to $660 million and this range includes a $50 million dollar US NDA milestone.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 99.2</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU9"></a><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">At September 30, 2019 FibroGen had $665.5 million in cash, restricted time deposits, cash equivalents, investments and receivables.&nbsp;&nbsp;</font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Thank you. And I would now like to turn the call back over to Jim.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">James A. Schoeneck</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As you have heard we've made significant progress over the past few months. Looking forward we'll continue to drive our products, programs, and organization. Here are some of our areas of focus. First FibroGen's Board and our Search Committee has initiated a search to find a truly exceptional leader to be FibroGen's permanent CEO. We'll update you as we have more news about selection.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:0%;color:#212121;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For pamrevlumab we<font style="color:#000000;">'re</font> enrolling in our <font style="color:#000000;">Phase</font> 3 studies <font style="color:#000000;">for</font> both IPF and locally advanced pancreatic cancer<font style="color:#000000;"> and we'll</font> focus on opening additional study sites <font style="color:#000000;">in</font> increasing patient enrollment. <font style="color:#000000;">We also</font> look forward to discussions with the FDA to determine the next steps <font style="color:#000000;">in</font> our <font style="color:#000000;">Duchenne</font> muscular dystrophy program. In China our focus is on securing reimbursement and the upcoming r<font style="color:#000000;">oxadustat</font> launch.&nbsp;&nbsp;We look forward to updating you on <font style="color:#000000;">that</font> progress in the coming months,<font style="color:#000000;"> as well</font>. </p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For roxadustat<font style="color:#212121;"> we are completing our NDA submission in conjunction with </font>AstraZeneca<font style="color:#212121;"> and</font> <font style="color:#212121;">plan to file by the end of this quarter followed by the European MAA submission through our </font>partner<font style="color:#212121;"> Astellas by March </font>of <font style="color:#212121;">2020.&nbsp;&nbsp;As </font>Pat mentioned<font style="color:#212121;"> FibroGen is eligible to receive $180 million in filing milestones from our partners</font> and we<font style="color:#212121;"> are also eligible </font>to receive similar scope<font style="color:#212121;"> approval milestones. </font></p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Finally, we<font style="color:#212121;"> plan to submit the data just presented at </font>the <font style="color:#212121;">ASN for publication and we</font>'<font style="color:#212121;">ll continue to seek </font>out <font style="color:#212121;">new indications for roxadustat with our programs in MDS and CIA.&nbsp;&nbsp;</font></p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:0%;color:#212121;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">At this point, I'd like to open <font style="color:#000000;">up </font>the call for questions<font style="color:#000000;">.</font></p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Question and Answer Section</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operator</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">And your first question comes from Michael Yee. Michael, your line is open.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:0%;color:#212121;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Q</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Michael J. Yee</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Thanks very much. I appreciate the questions, and congrats on the progress. I know Tom would have been proud, had he been there and congrats on the progress.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:0%;color:#212121;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Thank you.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Q</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Michael J. Yee</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Two questions. One is for Peony, I would just like to understand since there seems to be some investor concern about FDA agreements and FDA signed off on statistical plans. How you are general impression-wise of your meeting with the FDA. And why do you feel confident about statistical protocols and their signing off of what you have from statics and why you feel good about that?</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 99.2</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU10"></a><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">And my second question is for Jim; in your seat, although I appreciate you're the interim CEO, perhaps you could talk about what </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">your priorities are, and what the board's priorities are at this point given where the stock is at, where things are, and I guess what you're thinking about in terms of priorities from here. I appreciate it. Thanks.</font></p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Peony Yu</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Mike, thank you the good question. First of all, I wanted to share that we have been in dialogue with the FDA in the past six years.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">And there has been a very good understanding about what the Phase 3 require study would look like and including the size of the study, how to power it and what the primary endpoint. And we agree on time to MACE as the primary endpoint, and that's how we power for the non-dialysis and the dialysis. And we've also had a very productive dialogue with the FDA on the analysis of cardiovascular safety as well as what the efficacy requirement needs to be for this submission.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">And the most recent conversation with the FDA was at the end of July. And we had sent it to the FDA, a fairly comprehensive briefing package, and had a very productive meeting. And walking out of it, we thought that we had all the guidance from the FDA we needed to put together a winning submission. And that is about to be out the door this quarter.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Q</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">So, you feel no issue or no real concern about the hazard ratios and the upper bounds and all of the things that people are talking about. You look at diabetes programs and things like that, there is &#8211; you're well within that, so you don't feel any concern about that.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">No, we have no concern about that. And, Mike, as you know, that a regulatory assessment is not based on one criterion, but instead, it is based on totality of evidence such as efficacy, safety, what is the medical need.&nbsp;&nbsp;And so based on our discussions and the historical precedents in this therapeutic area and the various conversations we've had with the agency we are very comfortable with our data, where it is now.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Q</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Okay. Thanks. And Jim, just for that question for you.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">And Mike, I think our focus is very clear as I mentioned through my closing remarks. I mean, first and foremost, it's filing of the NDA. Second, it's filing through Astellas, the MAA in Europe. Behind that is China and securing reimbursement along with the support and our participation in the China launch and with pamrevlumab it's around accelerating both the number of sites and the enrollment in our two Phase 3 studies and getting agree with the FDA on where we're taking the DMD program next. Beyond that, we're working with the rest of the Board, it's finding a very capable person to step in and lead the company longer term.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Q</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Okay. Thank you.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 99.2</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU11"></a><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operator</font></p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">And your next question that comes from Geoffrey Porges. Your line is open.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Q</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Thank you. Thank you very much, and thanks everybody for participating in the call. I just want to also share my sadness and sympathy about Tom and particularly poignant given all the recognition and progress that you've made with roxadustat and pamrevlumab.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Thank you, Geoff.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Q</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">So one question for Peony, if I may, and one question for Chris. Peony, could you share the number of patients in the non-dialysis cohorts that progressed to dialysis and the difference in timing in the progression of dialysis and perhaps comment about whether the patients post-progression-to-dialysis presumably were treated with EPO and behaved in the same way as the incident dialysis patients and so is there a benefit from the comparison between ROXA and EPO in the patients who progressed. And then, Chris could you talk a little bit more about the NRDL listing, specifically, have you applied to both dialysis and non-dialysis, and what is the size of the non-dialysis patient population who are anemic enough to justify treatment with an innovative drug such as ROXA? Thanks.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Geoff, you asked a lot of -- noticed that the question is more than one. So, I think that &#8211; it is correct to expect that when 30% of the other than non-dialysis patient pool were indeed already had &#8211; already reached end stage kidney disease, meaning eGFR being below 15, than you do expect some patients to required dialysis treatment in this long-term outcome program. And so, we the &#8211; now the analysis of these patients is important because transition &#8211; that presents a transition to dialysis. And we have not had a chance &#8211; as you see, we have &#8211; we have presented a lot of data at the ASN. We have not had a chance to write this one up yet and we agree with you this is important that we should present in future medical conferences or publications. There's a little bit complicated to report that as a Q&amp;A over here.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">I'm sorry.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Q</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Was there a benefit at least in time, was there a significant difference in the time to progression to dialysis between the two cohorts?</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Based on the results from the eGFR change, we believe there should be, but the data needs further analysis, mainly because the time on treatments between roxadustat and placebo differ.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 99.2</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU12"></a><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Q</font></p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Okay. Thanks. Chris, I'd love to hear from you about NRDL?</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Hi, Geoff. So your first question I believe is whether roxadustat was invited by the Chinese Government to NRDL negotiations. So first of all you're absolutely right, a sponsor is invited, you don't proactively apply. So I think consistent with what AstraZeneca partners have said, the two companies are collectively putting a lot of effort in getting into NRDL, at this point in time we're not discussing if there is an invitation primarily because all invitations either to roxadustat or to other companies are considered confidential and the Chinese government has not published a list of companies invited to negotiate. So I would prefer to wait until the end of the year when the outcomes from NRDL is disclosed. I hope you understand.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Q</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sure.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">With regard to the second question I believe the question was what is the size &#8211; potential market size of non-dialysis. So I had mentioned just now in my section of the script that there are over 600,000 dialysis patients in China 90% to 95% of them are anemic.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">90% to 95% of them are anemic. In non-dialysis if you look at the CKD population exactly a 120 million of course mostly they are early stage and they're not necessarily anemic. If you look at Stage 3b it's about 50% anemic State 4 about 70%, Stage 5 non-dialysis it's about 90%. If we add those numbers up based on the real world evidence data that we have measuring hemoglobin 10 and below we believe the addressable market in China for non-dialysis patients but low hemoglobin 8 is close to 2 million patients. It's a substantial population. And, Geoff, we're very excited because we have an oral therapeutic with a safety profile that we think would greatly expand the addressable market.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Q</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Great. Thank you very much for that, Chris.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operator</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">And your next question comes from Adam Walsh. Your line is open.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Q</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Edwin Zhang</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Hi. This is Edwin on for Adam. Thanks for the question. First question maybe for Peony, for the individual MACE components in the NDD, I guess that events for myocardial infarction and the stroke, in the data set are small and FDA will focus on the MACE composite. Can you please further clarify on this NDDs MACE data set?</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 99.2</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU13"></a><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A</font></p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Yes. So I wanted to reiterate that in our conversation with the FDA, the primary safety endpoint was the composite MACE and there was never any requirement stated for us to&nbsp;&nbsp;-- on the individual component itself. And I also again remind ourselves that these numbers are fairly &#8211; the number of events are fairly small. And that &#8211; now, another thing to point out is that the lower of the 95% confidence interval on each of these individual components are below 1.0, which is very different than the stroke in TREAT. And we're looking at the overall picture and the overall safety profile off the drug, looking at efficacy, safety, as well as what &#8211; how little is on the market for treating the non-dialysis patients.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Q</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Okay. My second question is, when are you going to talk [Technical Difficulty], I mean the statistical analysis plan, including the non-inferiority market? Is there &#8211; [Technical Difficulty] FDA meeting in the coming weeks?</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">I am sorry about the questions. Are you asking when we will publish these results? We do plan to write it up as soon as we can and put it in a scientific journal.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">I think &#8211; Adam, I think the question is, when will we talk to the FDA about the statistics and the analytical plan, is the question.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Q</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Right.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Do we plan to talk to them in the coming weeks?</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Oh, okay. So, the answer to that question is that we had already talked with the FDA about analytical plan and we had a -- made the agreement on the analysis plan that that we have presented in high impact clinical session at the ASN and the numbers I had just presented were based on the agreed analysis plan that we have made with the FDA.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Q</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">So the non-inferiority margin of 1.3% is already in agreement or not?</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">So we are talking about the analysis plan meaning how do you prove you know what's the proven strategy and the analysis plan how to analyze the data. When you talk about NI margins, we're -- you're talking about the standard for assessment, right? And as I mentioned earlier that we expect that all regulators will assess the data based on very you know on the entire application of the NDA and based upon our dialogue with the FDA with the past six years and that data as we have shown, we are confident that we do have what it takes for this drug to be favorably evaluated.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 99.2</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU14"></a><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Q</font></p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">All right. Maybe another question for Chris regarding the China market, can you help us understand more of the safety market there and how do you -- and AstraZeneca book a revenue across China, is it 50-50? Thank you.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Thank you.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">So, Edwin, with regard to the first question about the self-pay market. So the self-pay market is not large, and this is why getting into NRDL it's an important inflection point for the business. The self-pay market is basically people not getting reimbursement and choosing to pay a 100% out-of-pocket, at a price and you know it's visible to the market for a roxadustat drug that is higher than the standard of care. We have sales at this point in time, so there is a self-pay market, but we do not expect it to be substantial because of that differential in pricing.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">With regard to revenue recognition, FibroGen is the marketing authorization holder of roxadustat in China. And under the two invoices rule it is the manufacturing, it's the marketing authorization holder that books revenues. We have a 50/50 profit share with AstraZeneca. So that is how the 50/50 works is not a 50/50 split of the top line, it's a 50/50 split of the profits.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Q</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">That's very helpful. Thank you.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">You&#8217;re welcome.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operator</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">And your next question comes from Danielle. Your line is open.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Q</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Hi, thanks for taking my question and congratulation on the data. I just had a couple of questions. This is Nirav on for Danielle, by the way. I was just wondering, would you be able to talk a little about whether you're expecting priority review or normal review with the NDA and if you'd be willing to use a priority review voucher?</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This is a very good question. And we believe that the basis for priority review could be because we have a new innovative drug that is potentially better than what is available, so treating diseases in patients was a serious condition. However, the decision whether to grant us power to review is that one of the FDA.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">So, the second part of your question, I would not see us using a priority review voucher, but we will indeed request priority review.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Q</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Okay. I see. Thank you. That's helpful. And I guess my second question would be, would you be able to give us just some color on the MDS study? Just how it's going? How the enrollment's going? And when we should expect data? And along with other agents that are currently in the pipeline for the indication as well, how do you see roxadustat sort of fitting in from a strategic standpoint?</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 99.2</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU15"></a><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A</font></p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Good question. We do &#8211; we are seeing encouraging data from the open label portion of our Phase 3 study, which is what we will be presenting in the upcoming ASH. And since the other --&nbsp;&nbsp;so, in terms of -- of the competitive landscape, we believe that because MDS is such a &#8211; MDS anemia is a condition that there's so much need, and so, difficult to treat. We believe that there are &#8211; there is still opportunity for us to make a difference in these patients. And the moment is ongoing and we will come back with a &#8211; in the future with timeline on the when the study will be completed.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Q</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Great. Thank you so much.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Thank you.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operator</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">And your next question comes from Paul Choi. Your line is open.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Q</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Hi, everyone, great to see everyone at the ASN meeting, and thanks for taking the question. My first question is for Peony and you did state earlier that -- that the non-dialysis population was not powered to individually assess the various components of MACE, but given the background of the patient population in terms of their eGFR level, can you give us, what is your understanding with regard to the FDA's position on the individual components with respect to when a trial is non-powered to show a statistical difference on those individual points, given the patients -- background population? And that I had a second commercial question on the NRDL.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">So to you &#8211; we can share our view on the individual components and what that discussion with the FDA in terms of the requirement for our primary safety endpoints. And, as I stated earlier, there was never any explicit expectation on the individual components. Now, but I we do believe that the evaluations of the data have to take into account the overall benefit risk of the drug for a patient. So, I hope this answers the question.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Q</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Oh, yes. Thank you. And then, on the NRDL, I know you stated you haven't &#8211; you won't formally communicate whether you &#8211; whether roxadustat is under invitation to be considered. But assuming -assuming it is under consideration, I guess as you think about you know potential reference price -pricing in the competitive landscape given the wide availability of EPO in China, can you maybe give us what you think of a reasonable range is potentially for pricing on the go forward given the &#8211; given the availability and pricing of EPO in the China market? Thank you very much.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 99.2</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU16"></a><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A</font></p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Absolutely, Paul. So, the way we think about pricing in China is as follows. So, first of all, as value-based pricing, we evaluate the scope of unmet medical need and the pharmacoeconomic consequences of not treating or not treating optimally or not treating safely. We've then compared the clinical efficacy benefits of roxadustat based on the China Phase 3 studies over ESAs and then we'd looked at the safety advantages over ESAs and this is all about differentiation on a clinical basis. We also with AstraZeneca believe that roxadustat as a first-in-class drug and a patented first-in-class drug of course to state the obvious deserves that innovation premium because we are bringing a transformative new treatment paradigm to China debt above and beyond to clinical benefit to the patient in a quantifiable unmet medical need also supports the country's policy direction of encouraging innovation. So we're hopeful that roxadustat could become an example of companies bringing innovation to China and expecting a return for that delivery.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We do not see ourselves being benchmarked against locally manufactured ESA because we think we're a highly differentiated product with clinical benefits and we believe we deserve an innovation premium.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Obviously, Paul, at the end of the day it's about budgetary concerns and budgetary considerations of the Chinese government and affordability for the patient. So at the end of the day should there be an NRDL negotiations pricing would not just be what we would like to assert but what the country can actually afford. So, we'd be eager to see what that balance is should there be an NRDL negotiation but that is our pricing strategy in terms of what we will believe it's a fair pricing for roxadustat.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Q</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Thanks for taking our questions.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operator</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Okay. And your next question comes from Joel Beatty. Your line is open. Joel perhaps you're muted on your end.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Q</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Joel L. Beatty</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Citigroup Global Markets, Inc.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sorry about that. Okay. Can you hear me now?</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We can, Joel.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Q</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Joel L. Beatty</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Citigroup Global Markets, Inc.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Hi. Okay. Oh great. So the first question is on quality of life benefit from the Phase 3 program. I believe that there were some initial data presented in the top line data but then I didn't see anything on quality-of-life ASN, should we still consider quality-of-life effect to be in line with the top line press release, and how important. Well quality-of-life data from the Phase 3 program for marketing the drug?</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 99.2</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU17"></a><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A</font></p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Joel, it is a great question. Yes, our data is consistent with what we had reported in top line. And we just have so much to put together for the ASN and we do look forward to present the results in future conferences and publications. As you know one of the manifestations of anemia is for patients' fatigue and loss in quality of life. Thank you.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Q</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Okay. And maybe one other question, could you talk about the indications you plan to pursue for roxadustat? Thanks.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Yes. So we and our partners believe that roxadustat has the potential to become the anemia drug for various kinds of anemia beyond CKD. And as we have presented, we already have ongoing trials in MDS anemia and in chemotherapy induced anemia, and there are additional anemia types that are in consideration such as anemia in multiple myeloma patients and anemia of inflammation. There has been extensive effort to evaluate all these types of anemia and more.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Q</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Thank you.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operator</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Okay. And there are no questions at this time.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">James Schoeneck</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On<font style="color:#212121;"> closing, I</font>'<font style="color:#212121;">d like to thank </font>you<font style="color:#212121;"> for your</font> attention and<font style="color:#212121;"> support.&nbsp;&nbsp;I also want to thank the senior </font>management <font style="color:#212121;">team and all the dedicated employees at FibroGen in the US and </font>in <font style="color:#212121;">China who are committed to bringing novel innovative medicines to patients around the world fulfilling the vision that Tom set for the company 25 years ago.</font> Thank you.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operator</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Thank you, ladies and gentlemen. This concludes today's conference. Thank you for participating. You may now disconnect.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>gfo20dp4oa1x000003.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gfo20dp4oa1x000003.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" $# 7L# 2(  A$! Q$!_\0
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M9<-D\L/E/'K0!S]MX"\1:-XJT'3]'U26V%AH<L!U7[%OB9C.6V%2< X;/7/
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MJ @O8F&ZAW<KOSD9'<9JMHO@SQ%I<^GV\OC.XGT?3R!#;+:(DDB*,*DDF3N
M''09KG/$?Q"UFP\7:[IL6N>']+@T](F@CU&%VDG+1[B 5;G!XX'<5J:AXYU^
M7P1X<N-.TZ"'Q)KCJD-K<*VQ  6=B,@[=HS[;A0 Z+X7RQW$-B=?E;PU#?\
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M'GTSRS&2<R'[^<]!Z5C:?\.M;EAT/3]>\06]UH^C/%+!:VUGY1D>,83>Q8Y
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MQE;)/.\Y(W#E7=3&,AMH4%=PRW)P* /2:*R]$U5]8BN;@0>5;),8H&W9,FW
M9OIOW >NW/>L"V\7ZUJ.N.NG>'/M&B0WS6$MY]J"RAE.UY!&1RBMQUSP3B@#
MLZ*X_P -^-GUJ\T^"XLDMQ?P7,L++(6RT$YC9>@[%6_,=J["@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH Y?XB?\B1>_P#76W_]'QUU%<O\1/\ D2+W_KK;_P#H^.NH
MH **** "BBB@#/M%4:UJ+"*16*Q9=C\K<'IQV[TS6]#M=>M[:"[:0);W45TN
MPCEHVW '(/&1S3[5E.M:BHED9@L648?*O!Z<]^]:% ',OX&TF35FU%C-O:^6
M_,7R^7O$/DXQM^[M.<>O>DF\%VJ>#-6\-VEQ,+6\298$E8,+;>.%3C.Q3R <
MXZ5T]% '*)X+M[[5=.UO59)FU"WACS CJ8DE5"NY6VA\#<Q SC/.,U8LO"*Z
M>+^>/5M0GU&[MQ;+?73K))#&N[:%P ."Q.3DD]2:UM1U>PTE(WOK@0B0D+E2
M<XY)X'0=ST%%_JUEID"SW4K+$P)#I$SC &<G:#@8[FE=%JG-VLMS)T?P?:Z)
MKDFH6MS,(C;"W2V/W44!!U[_ .K&/0LWK59_A]IA\0?VHE]JD,1NA>OI\5T5
MMGG_ .>A0#.2<$C.">U;,7B#2I[J"UCO%,TZ*\:[6&01N'., D<X/.*TZ$T]
MA2A*/Q*QR6E^#AI6OZ9+!(6T_3;6Y6'S'S(TMQ*'?. !@ 8'U]JZVBBF2%%%
M% !1110 4444 %%%% !17F'Q@EU5)/#<>DWD]O<&ZFEQ%(5\SRXC(%;'4';C
MGUKFM(\;W*>*_$'BV>[N6TR?19;RRM)7.P!)5B0!<X!9E_\ 'J /=**\'\+^
M,-5TSPYXFL(KZ_O=273!J=M)>PNKK+M G50XY56PPQQUKHK&+1]/L)KG3/'-
M_?WMUI$\K6TM_P"?YS"/=Y@'5"#Z8_2@#U:BO&OA0)[B\TVZNXKL2/9"3[1+
MXC%R)F*C.;?.5R"3@_=Q7LM !1110 4444 %%8GB;5-2TFRM9=*T[[?<2W<<
M)AR1\K9R<_P]!R>!FL_^W?%__0EI_P"#6/\ ^)J'-)V.B&&G.*DFK>;2_-HZ
MNBN4_MWQ?_T):?\ @UC_ /B:/[=\7_\ 0EI_X-8__B:/:+S^YC^J5.\?_ H_
MYG5T5RG]N^+_ /H2T_\ !K'_ /$T?V[XO_Z$M/\ P:Q__$T>T7G]S#ZI4[Q_
M\"C_ )G5T5RG]N^+\?\ (EK_ .#6/_XFN)\.^/\ QC?^+]0M#HIN^N;$N(OL
MNWC[Y'YYZGI4NM%-+77R-J>75JD923C[JO\ $O\ /\SV&BN4_MWQ?_T):?\
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MM([BYDED34A:7"OL8,'CW+AE !P<'H.I'-=G6D9*1RU:,J;LPHHHJC(****
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M?'744 %%%% !1110!GVK@ZSJ"B9V*K%F,CY4X/3GO6A5"V9CJ]^IF1E"Q8C
MY3@]>._U-7Z "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHKE/B+XCU
M+PMX3?4=)@@GO3<10QQSJ2K%V"]B/7UH ZNBO,K'XEWNJ>./#NDVEO:G3K^T
M#W4I#%TG,32%%YP, #.0>M6_#/Q"N=7\1WL%];00Z5/'-/I$\>=T\<+E)-W/
M4\,,8XH ]"HK@_#?B#QIKQT[61IVD#0+]MRPB5Q<PQ'.UV)^5C_L@=ZY[PS\
M2]8USQ+#83:OX;@#7DD+6/V>X^TE$9APV=FXJN1VH ]=HKB_#OQ.\/>)O$UY
MHMA=1O)'M-LX+'[2-FYR 5&W;C')YKM* "BBB@ HHHH **YN\\>^&].U2ZTZ
M^U%;:YMF5761&P<J&&"!SP:B_P"%D>$/^@Y!_P!\O_A4>TAW.A8/$-75-_<S
MJ:*Y;_A9'A#_ *#D'_?+_P"%'_"R/"'_ $'(/^^7_P */:0[H?U/$_\ /N7W
M,ZFBN6_X61X0_P"@Y!_WR_\ A3)?B7X0BB>3^V8GVJ3M1&)/L..M'M(=T'U+
M$_\ /N7W,ZRBN!T+XM^'=3MI7OY?[-F1R!'+EMR]B"!^8K5_X61X0_Z#D'_?
M+_X4E5@U>Y4\!BH2<73?W,ZFBN6_X61X0_Z#D'_?+_X4?\+(\(?]!R#_ +Y?
M_"G[2'=$_4\3_P ^Y?<SJ:*Y;_A9'A#_ *#D'_?+_P"%'_"R/"'_ $'(/^^7
M_P */:0[H/J>)_Y]R^YG4T5B:-XMT7Q#>SVNE7?VEH(UD=E0A0"2,9/?BMNJ
M335T8U*<Z<N6:L_,Y?XB?\B1>_\ 76W_ /1\==17+_$3_D2+W_KK;_\ H^.N
MHID!1110 4444 4+8-_:]^2D04K%AE(WG@_>Y_*K]4+5,:QJ#_9V3<L7[TDX
MDP#T^G]:OT %%5-3U"/3+%KF16?#*BHO5V8A0!^)JC:>(X+O5S8""5 6E2*9
ML;9&C(#@<Y&">XYYI.23L:1I3E'F2T&>*IY(-*B*S/!"]U"ES*C%2D18!CN'
MW?KVS6!)K5RG@>5(;QC>9=HG9B7^S";9YF>N-I'S?C6U)XLLEU/4+)XLQV*,
MT\AD3H$W'"9W'KCIUJYH^JQ:JLZFT>VG@VJ\4FTD*RAEY!(P0:S=I/1G5'FI
MTUS0V:?]?UV."N]6OTM+8"[<6L(N"CBZDQ=.CJ%$;YR<@G:"6'7K7J$9+1*Q
M!!(!(/45BW'B"TMM8336M9&1)8XFF 79'(X)1<9SR!U XR*6_P#$L%AK4.FO
M;3.TAC!D4K@;R0N 3EN0<X!QWHC:-[L*W/52486W?WFW17-1^-+-XII6M;A(
MTC$Z,=O[R$OL+CG@ \D'G%=+U&16BDGL<LZ4Z?Q*P4444S,**** "BBB@ K(
M\1^'X/$FG0V5Q+)%''<Q7.4 R3&P8#GL<5KT4 <#%\*]/M)#+9:E=VTWVN[N
MTD54)1KB/RR!D=%'(]Z=I_PE\-:/<Z3=Z3%)9WM@ZL]PC%FN5VE75P<C# G.
M /:N\HH XS3/AY%I-_:FVU_61I=G*9K;3// AC//RY W,@R<*3BH]'\ 7FAW
M,?V+Q9JB6*W37!LO*BV-N<NRD[<X))[]Z[>B@"A::-8V.J7^I6\.VZOS&9VW
M$AMB[5P.@X]*OT44 %%%% !1110!6BT^T@N;BXBMXUFN6#3.!RY P"?PJ?RT
M_N+^5.HHL-R;W8WRT_N+^5'EI_<7\J=10%V-\M/[B_E45U96M[:RVUS;QRP2
MJ5=&7(8&IZ* 4FG=&!X:\':/X5@FCTZ EIG+/+*=SD9X7/H*W?+3^XOY4ZBD
MHI*R+J59U).<W=L;Y:?W%_*CRT_N+^5.HID78WRT_N+^5'EI_<7\J=10%V5T
ML+6.^DO4@1;F1!&\H'+*"2!^IJQ110#;>YR_Q$_Y$B]_ZZV__H^.NHKE_B)_
MR)%[_P!=;?\ ]'QUU% @HHHH **** ,ZTV?VWJ6T2;]L6XM]WH<8_K6C5"U?
M.L:@GGN^U8OW1!PG!Z?7^E7Z ,GQ%93WNF)]F3S)H+B*X5,@;]C@D<^V:HCP
MR]M>2W<.I>4%,[VH:$'R'E(+$\_,,C@<=>]=)7.^+;6YU&'3].MX1()[M6E,
MB%HPB M\^.Q( ZUG.*W.FA4EI33LM1+SPP-6N6>ZOEDM2)"D<4"HP9TV$EP>
M>_;ZDXIUAH][IUTKI?I/--,K7C>4%W1+'M50,G!X!SWYK!F\/ZWI<K)IYOW2
M9C-(NG30V\,;$_=5'!/0#O3M/@NK'Q"]Y-971F@>[ENY5B),T9V^4H/1SQP!
MTP>E1=7V.IQDX64TU;:R_I?YV-ZZ\.)<Z[]L^V[8VEBN)+?8"6>,$(0V>!TR
M,<XJM/X9>YO;>_N=661T\KS9/)4$F-B1L;/[O.<$#.:Q+RPU*?6+Q[6VN$OY
M)9Y%N3&0# T&$7?T^]QM[$9J!-*673Y=]M?6FG^? RQ)8F0F18B')C(/&[&3
M@@D?C2;78J,))+W^BZ+^O^&\C6N?"#0V6IR6LB3W%]%]G01QB-41WRQ/.#C.
M>,#CIDUV4:".-4'10 ,U1T(7(T*Q%W;I;W A7?$BA0AQTP.GT[5H5K&*6J.&
MM5G-\LG>S_K\@HHHJS **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH Y?XB?\B1>_P#76W_]'QUU
M%<O\1/\ D2+W_KK;_P#H^.NHH **** "BBB@"A;%CJ]^#)&RA8L(H^9>#UX[
M]N35^J%LK#5[\F.-5*Q8=3\S<'KSV[<"K] !1110 4444 %%%% !1110 444
M4 %%%% !1110!0N=;TRTU:TTJXO88[^[#&W@9L-(!UP/PJ&?Q+HMM>2VDVHP
M)<13Q6[QEN5DE&8U/NPZ5Y1XGT?QAK/B/6O$FGZ)$WV"YA&G/<,Z7 6V)9O*
M3'S+(68=>:L:KI>JZCXHO=0BTB_6&YUO1+I=T# A$3]X3Q_ 3AO2@#U36-=T
MKP_9_:]7O[>R@+;0\SA03Z#U/TJ;3M3L=7L8[W3KN&ZM9!\DL+AE/XBN-\:6
MUU:>+M!\1'1KG6-/LH9X9;>UC$LL+OMVR*A^]]T@XY&:Y_7QJ=]H6G)I?A;4
M]$M+JYN9)H[5&\U6V_NV>*)EP7;^\<*1SF@#URBO$+A_&$6AN9K3Q!-=7?A>
M.W0Q1R,R7:R-N+8^Z^,<GD^]:UU!X@M_'MC=1PZS>QLUJIA/G11P+L <K(K&
M-ESDLLBAB>E 'K-%>4>!;/Q<GC+S=7FU'C[3]O$L+B!_G_=;69RC<8(\M1@9
M#5ZO0 4444 %%%% !1134=)!E&5AG&5.>: '4444 %%%% !1110 450UG6M.
M\/Z7-J6J74=M:Q#+.Y[]@!W)[ 56\-^)](\6:4NHZ/=K<0$X8=&C;^ZR]0:
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M/&-Q/*'2P,MY)+,UUYB77FR!X]L?_+-E^;<<#/OV]&H **** "BBB@ HHHH
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M\R"2,>,_%YW*1\VJ$CD=QMY%='X6T9O#OA;3='><3M9P+"90NT-COCM6O10
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MDFJR-;DMJT8BO#O;]XH0H!UX^4D<8H R-'\27=UKNFV%TL7EW^C)?QLBD$2
MJ)!UZ?.A'I@UU585IX;BM?$<.IHX$%KIRV%K  3Y:[LL22><[4'X'UK=H **
M** "BBL/Q;<:E;: 6TF1XKM[FWB$B0B4HKS(KMM((.%+'GIC- &Y17+_ /"/
M^)?^AUN__!?;_P#Q-'_"/^)?^AUN_P#P7V__ ,30!U%%<O\ \(_XE_Z'6[_\
M%]O_ /$T?\(_XE_Z'6[_ /!?;_\ Q- '445R_P#PC_B7_H=;O_P7V_\ \31_
MPC_B7_H=;O\ \%]O_P#$T =117+_ /"/^)?^AUN__!?;_P#Q-'_"/^)?^AUN
M_P#P7V__ ,30!U%%<O\ \(_XE_Z'6[_\%]O_ /$T?\(_XE_Z'6[_ /!?;_\
MQ- '445R_P#PC_B7_H=;O_P7V_\ \31_PC_B7_H=;O\ \%]O_P#$T =117+_
M /"/^)?^AUN__!?;_P#Q-'_"/^)?^AUN_P#P7V__ ,30!U%%<)8V'BZYUW5;
M&7Q9=QV]IY/DS?V; /-WJ2W)7!P>.*T_^$?\2_\ 0ZW?_@OM_P#XF@#J**Y?
M_A'_ !+_ -#K=_\ @OM__B:/^$?\2_\ 0ZW?_@OM_P#XF@#J**Y?_A'_ !+_
M -#K=_\ @OM__B:/^$?\2_\ 0ZW?_@OM_P#XF@#J**Y?_A'_ !+_ -#K=_\
M@OM__B:/^$?\2_\ 0ZW?_@OM_P#XF@#J**Y?_A'_ !+_ -#K=_\ @OM__B:/
M^$?\2_\ 0ZW?_@OM_P#XF@#J**Y?_A'_ !+_ -#K=_\ @OM__B:/^$?\2_\
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M^.V: )QXCT]VA2+[1+)*'(CCMW++L8*VX8^7!('-:U<C+H5U+IL,2:<!?!9
MMZUWMDBD<Y,A*CG)PV!_= QBNL0,L:JS;F  +8QD^M #J*** "BBB@ HHHH
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JBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>gfo20dp4oa1x000002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gfo20dp4oa1x000002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" #J <0# 2(  A$! Q$!_\0
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M&=4&68*/4G%-$T1.!(AYQPPH ?1110 4444 %%%% !1110 4444 %%%'09-
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MO&EQ=)]E>2/36>.1A^[8P'*YZ9!XK7\:Z]J&E2Z)INF206UQJUY]F%Y<)O2
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M;\<7&B1^*M<U:VU32)99[>&2?3=;LMR72",;&MI1\WS#^[CYNOM[PMM MO\
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MU:PL#N,:%0K9[$YXS5KPEXPN-9U>PCU?5(+:2.W$ MH\8O;D@[Y,C(" HRH
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MO$%';.YAQ4FD:[?^%/A1XIM;O4Y6U+^V7TJ"XN9F)1V1 S;CR HWM^% 'O\
M17B7ASQDVB^#?&VG:9K']K2Z*K7&GWCOYI>*11@DGKL;.:Z+1_#4&DKX;UP^
M,M1BO+UHO/\ MET98]0:1=WEA&. 3_#CI[T >ET5\_:%I]YK%UJTTV@^(]4
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M_/"+[_F?<'W_ .]]?>@#YYA+:;X+UCP7I,,ES<ZAXGN+%+:W<+(UO$$:7!/
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M*MW1\X[,6(!]S6CJRS)_PBBW)W3KJ""0YSEOL\N?UKI:P?$?_']X=_["@_\
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M(JNC##*PR"/0T(BQHJ(H5%&%51@ >E.HH *C6WA6=IUAC$SC#2!1N(]S4E%
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MK(PPRL,@BL3S_%?_ $#=&_\ !A+_ /&://\ %?\ T#=&_P#!A+_\9K,T-T#
MP.E%87G^*_\ H&Z-_P"#"7_XS1Y_BO\ Z!NC?^#"7_XS0!NT5A>?XK_Z!NC?
M^#"7_P",T>?XK_Z!NC?^#"7_ .,T ;M%87G^*_\ H&Z-_P"#"7_XS1Y_BO\
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M0VT$TTK@)#&9'QR0H&2<46=U#?64%Y;L6AGC66-B,95AD<?0UY8VB:U/KJ7
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M* "BBB@ HHHH **** "BBB@ J,P1&=9S$AF52JR%1N /49].!^5244 %%%%
;!1110 4444 %%%% !1110 4444 %%%% '__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>gfo20dp4oa1x000001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gfo20dp4oa1x000001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" #W 8<# 2(  A$! Q$!_\0
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MG P2"%./O'@<]<4L_P 6[&'2=/G.FNE_=S3P&TN+N*%8FA.)-TK$+U(QZYH
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M<36S2X<A>F]0P;_@-8VGW4OBA?#]N=8U(6.H>(M17S8+IXW:(+N0 YX XP*
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M[@A1)(/O!,G'')ZU-X<^'^HZ9XFM-5U35;.Z33H98;-;6Q6W9Q)U,NW@D <
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M<>3R"0!PV>-W7!(KIJ* ,/P=H'_",>$=-T=G$DMO%^]<=&D8EG(]MQ-;E%%
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M[A028@V<[N#VQQUH ZRBL[0];M/$&E1ZA9B18V9XVCE7:\;JQ5E8=B"#6C0
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MMOV2/'V7/E8VC[F>=OI6K67X:D67POI<BRQ3*UK&1)%%Y:-\HY"?PCV[5J4
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MVCVE_:PW-LY!:*9 RG!!&0?0@'\*L4 <'_PN+P7_ ,_UY_X+Y_\ XBL7P_\
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MUM_R-'^F^MO^1H LT56_TWUM_P C1_IOK;_D: +-%5O]-];?\C1_IOK;_D:
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MA\ L/<8R*7U9VO?0?ME>UCMJ*XCPOJ=P^MBUN+Z6^9XF8RQ3[XA@]60J"A[
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MR*21CD4&-&))123U)%%%  41CED4Y&#D=O2E"JI)"@$]<#K110 M%%% !2$
M]0#BBB@ (!&" 1[T;5P1M')R>***  @-U /UHP,YP,^M%%  % )( &>N!5,:
M7;C5Y-3RYG>$0D$_+M!R./6BBFI-;":3+FU3G('/!XHVKS\HYX/%%%(8;5V[
J=HV^F*"JGJH/&.E%%  0&&" ?J*6BB@ HHHH **** "BBB@ HHHH __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>7
<FILENAME>fgen-20191111.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- DFIN ActiveDisclosure(SM) XBRL Schema Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date      : 2019-11-09T02:46:17.6462742+00:00 -->
<!-- Version            : 5.0.0.208 -->
<!-- Package ID         : 341f72577fb545b38573953bec11aa7b -->
<!-- Copyright (c) 2019 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2018-01-31" xmlns:naics="http://xbrl.sec.gov/naics/2017-01-31" xmlns:invest="http://xbrl.sec.gov/invest/2013-01-31" xmlns:srt-types="http://fasb.org/srt-types/2019-01-31" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:srt="http://fasb.org/srt/2019-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2019-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:country="http://xbrl.sec.gov/country/2017-01-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:currency="http://xbrl.sec.gov/currency/2019-01-31" xmlns:us-types="http://fasb.org/us-types/2019-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2019-01-31" xmlns:fgen="http://www.fibrogen.com/20191111" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.fibrogen.com/20191111" xmlns:xsd="http://www.w3.org/2001/XMLSchema">
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance" />
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase" />
  <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd" namespace="http://xbrl.sec.gov/country/2017-01-31" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/currency/2019/currency-2019-01-31.xsd" namespace="http://xbrl.sec.gov/currency/2019-01-31" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd" namespace="http://xbrl.sec.gov/dei/2019-01-31" />
  <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/non-numeric" />
  <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/numeric" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/exch/2019/exch-2019-01-31.xsd" namespace="http://xbrl.sec.gov/exch/2019-01-31" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd" namespace="http://xbrl.sec.gov/invest/2013-01-31" />
  <xsd:import schemaLocation="http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd" namespace="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" />
  <xsd:import schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" namespace="http://www.xbrl.org/2009/role/negated" />
  <xsd:import schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd" namespace="http://www.xbrl.org/2009/role/net" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd" namespace="http://xbrl.sec.gov/naics/2017-01-31" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd" namespace="http://xbrl.sec.gov/sic/2011-01-31" />
  <xsd:import schemaLocation="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd" namespace="http://fasb.org/srt/2019-01-31" />
  <xsd:import schemaLocation="http://xbrl.fasb.org/srt/2019/elts/srt-roles-2019-01-31.xsd" namespace="http://fasb.org/srt-roles/2019-01-31" />
  <xsd:import schemaLocation="http://xbrl.fasb.org/srt/2019/elts/srt-types-2019-01-31.xsd" namespace="http://fasb.org/srt-types/2019-01-31" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd" namespace="http://xbrl.sec.gov/stpr/2018-01-31" />
  <xsd:import schemaLocation="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd" namespace="http://fasb.org/us-gaap/2019-01-31" />
  <xsd:import schemaLocation="http://xbrl.fasb.org/us-gaap/2019/elts/us-roles-2019-01-31.xsd" namespace="http://fasb.org/us-roles/2019-01-31" />
  <xsd:import schemaLocation="http://xbrl.fasb.org/us-gaap/2019/elts/us-types-2019-01-31.xsd" namespace="http://fasb.org/us-types/2019-01-31" />
  <xsd:annotation>
    <xsd:appinfo>
      <link:roleType id="TemplateLink" roleURI="http://www.fibrogen.com/20191111/role/TemplateLink" xmlns:link="http://www.xbrl.org/2003/linkbase">
        <link:definition>00000 - Document - Template Link</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="fgen-20191111_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:title="Label Links, all" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="fgen-20191111_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:title="Presentation Links, all" xlink:type="simple" />
      <link:roleType roleURI="http://www.fibrogen.com/20191111/taxonomy/role/DocumentDocumentAndEntityInformation" id="Role_DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>8
<FILENAME>fgen-20191111_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN ActiveDisclosure(SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date      : 2019-11-09T02:46:17.6462742+00:00 -->
<!-- Version            : 5.0.0.208 -->
<!-- Package ID         : 341f72577fb545b38573953bec11aa7b -->
<!-- Copyright (c) 2019 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://fasb.org/us-gaap/role/label/axisDefault" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-roles-2019-01-31.xsd#axisDefault" xlink:type="simple" />
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Central Index Key</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amendment Flag</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Period End Date</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Registrant Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Emerging Growth Company</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity File Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity File Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Incorporation, State or Country Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation State Country Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Tax Identification Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line One</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address Address Line1</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, City or Town</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address City Or Town</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, State or Province</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address State Or Province</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Postal Zip Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address Postal Zip Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">City Area Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Local Phone Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:label xml:lang="en-US" xlink:label="dei_WrittenCommunications_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Written Communications</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_WrittenCommunications_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Written Communications</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:label xml:lang="en-US" xlink:label="dei_SolicitingMaterial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Soliciting Material</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SolicitingMaterial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Soliciting Material</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre-commencement Tender Offer</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre Commencement Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre-commencement Issuer Tender Offer</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre Commencement Issuer Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Title of each class</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security12b Title</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trading Symbol</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Name of each exchange on which registered</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>9
<FILENAME>fgen-20191111_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN ActiveDisclosure(SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date      : 2019-11-09T02:46:17.6462742+00:00 -->
<!-- Version            : 5.0.0.208 -->
<!-- Package ID         : 341f72577fb545b38573953bec11aa7b -->
<!-- Copyright (c) 2019 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.fibrogen.com/20191111/role/TemplateLink" xlink:href="fgen-20191111.xsd#TemplateLink" xlink:type="simple" />
  <link:roleRef roleURI="http://www.fibrogen.com/20191111/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:href="fgen-20191111.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.fibrogen.com/20191111/taxonomy/role/DocumentDocumentAndEntityInformation">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="10150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince" order="10230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="10250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="10270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="10290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_WrittenCommunications" order="10310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SolicitingMaterial" order="10330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementTenderOffer" order="10350.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementIssuerTenderOffer" order="10370.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="10390.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="10430.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="10470.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>12
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "fgen-8k_20191111.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "contextCount": 1,
   "dts": {
    "definitionLink": {
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-eedm-def-2019-01-31.xml",
      "http://xbrl.fasb.org/srt/2019/elts/srt-eedm1-def-2019-01-31.xml"
     ]
    },
    "inline": {
     "local": [
      "fgen-8k_20191111.htm"
     ]
    },
    "labelLink": {
     "local": [
      "fgen-20191111_lab.xml"
     ],
     "remote": [
      "https://xbrl.sec.gov/dei/2019/dei-doc-2019-01-31.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "fgen-20191111_pre.xml"
     ]
    },
    "referenceLink": {
     "remote": [
      "https://xbrl.sec.gov/dei/2019/dei-ref-2019-01-31.xml"
     ]
    },
    "schema": {
     "local": [
      "fgen-20191111.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "https://xbrl.sec.gov/currency/2019/currency-2019-01-31.xsd",
      "https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "https://xbrl.sec.gov/exch/2019/exch-2019-01-31.xsd",
      "https://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd",
      "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd",
      "https://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd",
      "http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://xbrl.fasb.org/srt/2019/elts/srt-types-2019-01-31.xsd",
      "http://xbrl.fasb.org/srt/2019/elts/srt-roles-2019-01-31.xsd",
      "https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-roles-2019-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-types-2019-01-31.xsd",
      "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd"
     ]
    }
   },
   "elementCount": 23,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2019-01-31": 3,
    "total": 3
   },
   "keyCustom": 0,
   "keyStandard": 97,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "fgen",
   "nsuri": "http://www.fibrogen.com/20191111",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "body",
       "html"
      ],
      "baseRef": "fgen-8k_20191111.htm",
      "contextRef": "C_0000921299_20191111_20191111",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "100000 - Document - Document and Entity Information",
     "role": "http://www.fibrogen.com/20191111/taxonomy/role/DocumentDocumentAndEntityInformation",
     "shortName": "Document and Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "body",
       "html"
      ],
      "baseRef": "fgen-8k_20191111.htm",
      "contextRef": "C_0000921299_20191111_20191111",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.fibrogen.com/20191111/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.fibrogen.com/20191111/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.fibrogen.com/20191111/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.fibrogen.com/20191111/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address Address Line1",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.fibrogen.com/20191111/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address City Or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.fibrogen.com/20191111/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.fibrogen.com/20191111/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address State Or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.fibrogen.com/20191111/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.fibrogen.com/20191111/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.fibrogen.com/20191111/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.fibrogen.com/20191111/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation State Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.fibrogen.com/20191111/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.fibrogen.com/20191111/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.fibrogen.com/20191111/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.fibrogen.com/20191111/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre Commencement Issuer Tender Offer",
        "terseLabel": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.fibrogen.com/20191111/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre Commencement Tender Offer",
        "terseLabel": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.fibrogen.com/20191111/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Security12b Title",
        "terseLabel": "Title of each class"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.fibrogen.com/20191111/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Name of each exchange on which registered"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.fibrogen.com/20191111/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material",
        "terseLabel": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.fibrogen.com/20191111/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.fibrogen.com/20191111/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications",
        "terseLabel": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.fibrogen.com/20191111/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    }
   },
   "unitCount": 0
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r6": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.19.3</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>97</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="fgen-8k_20191111.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.fibrogen.com/20191111/taxonomy/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="fgen-8k_20191111.htm">fgen-8k_20191111.htm</File>
    <File>fgen-20191111.xsd</File>
    <File>fgen-20191111_lab.xml</File>
    <File>fgen-20191111_pre.xml</File>
    <File>fgen-ex991_6.htm</File>
    <File>fgen-ex992_142.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2019-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>14
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MMWF\81AU8\K(XK%T-8943OTJDH\ Q:X831F:3LTXXFBD(3^ G/,6+V2?$9/
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M/_QNPJXW]F#_L?%54+;PZR[D%U!+ P04    "  )0FQ/F5R<(Q &  "<)P
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M05\-_\GR"U!+ 0(4 Q0    (  E";$\?(\\#P    !,"   +
M  "  0    !?<F5L<R\N<F5L<U!+ 0(4 Q0    (  E";$\GZ(<.@@   +$
M   0              "  >D   !D;V-0<F]P<R]A<' N>&UL4$L! A0#%
M  @ "4)L3Q\F3ZON    *P(  !$              ( !F0$  &1O8U!R;W!S
M+V-O<F4N>&UL4$L! A0#%     @ "4)L3YE<G",0!@  G"<  !,
M     ( !M@(  'AL+W1H96UE+W1H96UE,2YX;6Q02P$"% ,4    "  )0FQ/
MG9(1L:$"  "3"P  &               @ 'W"   >&PO=V]R:W-H965T<R]S
M:&5E=#$N>&UL4$L! A0#%     @ "4)L3\FQ_298 @   08  !0
M     ( !S@L  'AL+W-H87)E9%-T<FEN9W,N>&UL4$L! A0#%     @ "4)L
M3[JA.8K7 0  ,@8   T              ( !6 X  'AL+W-T>6QE<RYX;6Q0
M2P$"% ,4    "  )0FQ/%FTC?T,!   \ @  #P              @ %:$
M>&PO=V]R:V)O;VLN>&UL4$L! A0#%     @ "4)L3__ )@B]    A0(  !H
M             ( !RA$  'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR96QS4$L!
M A0#%     @ "4)L3PN/V ,A 0  5P0  !,              ( !OQ(  %M#
G;VYT96YT7U1Y<&5S72YX;6Q02P4&      H "@"  @  $10

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6629111824">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th"><div>Nov. 11, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Nov. 11,  2019<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">FIBROGEN INC<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000921299<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-36740<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">77-0357827<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">409 Illinois Street<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">San Francisco<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">94158<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">415<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">978-1200<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of each class</a></td>
<td class="text">Common Stock, $0.01 par value<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">FGEN<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Name of each exchange on which registered</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>17
<FILENAME>0001564590-19-042608-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001564590-19-042608-xbrl.zip
M4$L#!!0    (  E";$]HD)58T00  'X7   1    9F=E;BTR,#$Y,3$Q,2YX
M<V2]6%MOVS84?A^P_\#IJ<4J2[+C.#:2%-W<  '<K'"RH6\%35$.49K22"JQ
M__U(2I1DFW8L)9WR$(KG]I'GHG-\^7&]HN )<T%2=N5%O= #F*$T)FQYY>7"
MAP(1XGV\_O67R]]\'TQO;N_ )R3)$YX2@6@J<H[?W7]Y#[[],9^!>_2(5Q!,
M4Y2O,)/ !X]29I,@>'Y^[L4)82*EN52F1 ^EJP#XOE7\)\=0$\ 42@S,,P']
M,!K[4>2'XX>P/SD[GT2CWOG9>7]TUO\]#"=AV%#P3W$&T'@F8-@+U5\_O&@P
M?H7H!UQB<#MM, [.HF34'XY&R6)X-EP,+H:CP7@X6& 411".%DVD:;;A9/DH
MP3OTWD!4YV4,4XHWX(8PR!"!%-S;DWX MPSUP"=*P5R+"3#' O,G'/=*K6L1
M3T1Q<\H;3$R8TI>OKKS&Y:T7G/92O@QBR0.YR7"@F'S%A3E!GI5[66A;0!!4
M"1AF@5%OF3X%BA"HHZFKC_Q!5+'+C!_@5Q0M<+$MP"!!PBUA2%IDM"U"V!,6
MTBU3T+308 <8E[X^7VTK@6)ACEZ1 A--6V):>;QC2\OTPW 8%,2&!:=NAU:5
M-4L(LWWVDN 0B3%QGU@1#N F;D\KZ -U3T*J,,26'Z4YDWSC-E$2':Z@A/TX
M8D63%U!45M9[_,\#PQV-Q^/ 4"M .>>JS!Q"5%+==WO SY;B$,)K].BVI"D.
M@62)V=9!$K+@J=HT54OS1^KQ )22DT4N\4W*5U.<P)RJ*,G9OSFD)"$X5L64
M8ET)MQ@:9 GY$LL[N,(B@PB?8K2\;!&[KEHY)@J^?9D5A=A3U04 4U_(*DNY
M!$69F:7(%-LCSM5OOHTC7V_Y45]=44\I\P!S CX4A,$K8=A ZP2CCM+.,&PM
MT/:'ARR[B\=I-L6QG+0O?IV@1S$<R^NN<)H)6;WY=>*<!LB5UAT1V;JH%VUQ
M[-;4;G'1_ [?%5]5'1]C'9_1^4GQZ?Z4OQ;.:[&TP['GF:JDFE5;W^P5Y(XH
M&IU"N?;KKN$D)(Y>HYMG*.<!Y(BG%*NO%9*?UQF%#,K4I'0K)VGV+5T^KI7=
MJ/?78#1*&5ZJ_CON!*RIX V R-> Z%YZZ[ZT6+8MN_M];4<@M@77"[_NQ4\"
ML=N^G^P,HV6OOPTPE<)TTB^G\\'F^,TP:!>+ED@*H9^#Q[2=;?'L]ZI=P\1.
M7F;EUS/8:8&R.[=UO)7F:%/<3+G3YEY<\]%;XFD=.%;FIR%J'3K.*:>!"#*6
M2@/#[-G=+",L2<LMM:F;XHD^VH-2!H@:)1[P2GU)))Z9*4V3_I[?OCR.%/5V
M6[C=\%B!LK!BG!!&S!%"_0"_^7N2-06TK<M@5V)762YP_!>[-NN,8Z&4F-MI
M2)<LQR01I"BG'01K9(?EREWKC1TGV7N:XP28$7I2?O^/#]I!QM,,<TE4J#3F
M=*/@D>/DRM,SKF_=^)W"14_YS;+L&=AVGG&Z$L%T5L.SLI)(+3S39.,E\0%
M6JG6X7OE"94ZM)K)_O?CJE!H>]S=Z'&?^FN#J_7AJX0\/?TD7*<L76T*C#9/
M[/]/+/[,%++-K<I^OC*H/)/N<\7^_23V8_D9.1*T6D(6@T(=:.AKE[*=$Z][
MKG=/V<M@M]:6.\V:7&P57XSK_P!02P,$%     @ "4)L3TUJA-PB!P  ETD
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M:9G_LQ*E*P*M>+8F15\.43KNBZ3#>$T\,!% \@^>EC];ZQ$,2)]"W'\U1'1
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M/4]5K-:,4<.L-QJC8;U6'U:;]4:U5:\.F648E#:&Z9EZ_E3PFW% ]JQ]-46
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M2_V=NE:KYRB G=G[H-#N"+N#]EU&*;].VSLZKP0M[G-YUA5:[X@K*K)"OM&
M=+Q 0#5ORV+\=\M#'PG:'6%WT.Z@W4&[589K9[2VA".V%-H=87?0[J#=0;M5
M1FO 7.X)\G=N,8('43G.\2 ^4\K4?5:=,6>CU"G3J]$(:HO7.5"S>!;CN#+T
M[*D:;!Q,'/CQ_U!+ P04    "  )0FQ/)AK9%NLX   :E 4 $    &9G96XM
M97@Y.3%?-BYH=&WM?6EWXDBR]O<Y9_Y#7O=R[7-EC-AQ===YW5ZZ/5.+IUQ]
M^\Q\N2>1$E"74&I2PB[/KW\C4A((##90-B12S%*V04MF+$\L&1GYTW]=?#S_
M_,^;2_;;Y_?OV,WOO[R[/F<'QR<G?]3/3TXN/E\D7S0J59M]5CR(O-B3 ?=/
M3BX_'+"#81R'IR<G]_?WE?MZ1:K!R>=/)\-XY#=.?"DC47%C]^#M7__R$WZF
M?PKNXL_8BWT!O_0'(C@67[M=^_]:%;@(OCK)OOOI)+OZOXZ/V8=?V;D,[H2*
MA6)WS4JU8G=K[7K%;MGL^!BOZDGW 7[^Y:>01?&#+WX^B,77^)C[WB X5=Y@
M&+\9<37P@N.>C&,Y.JV&DT]B&>;_]$4_/FU6&LT?WNAG>($K@OCT./FH+X/X
M^%[@$T][TG>3#R+O/^+4QH?H/_M\Y/D/IY^]D8C8!W'//LD1#])+<7BG@50C
M[B<OB)&V??@ /@U$<M4=5QZ'M[+TPH.WEU^'7L^+6;=;L7\Z"=\NGJH#0Q4J
M/S.[$RZ:>WYJU:>G57O-:5UY/25_%0'[)$*IXHA]'GK*9?\8<\WL6M7NLBLO
MX('C<1\NBL9^',W-?RW.MBNU]@_9)UHR3FN56NV'9RF2)XD-#SUX^V/0B\(W
MR6!<[XYI%OQ\@*\Y@(]BWO,%ZTGE"O7S0?6 .<+WHY [7C"8_!URU\W^SN:3
MW'+L2-_G821.LU_>L'O/C8<@:# ^_0:%_[CL+GTSS/<@>TAR:;W2:OSPYG[H
MQ>(87XTLNE<\/%B+?GE:I)S[!J8_+TL+:0S@X&YQNM-!/#O>%Z/,P=N?\/-L
MH#L<QX_?=6IV#>B.W[]=3OY]$:/'='T,=GH47@RS<^".3_(K=\=1S&-V(]'T
MW0GX1?K"93=#'@E69Y?]ON=PYX'QP&7G7+F>O..1,_:Y8K>\+^('=L%CSFZ4
MB!"77?:.1S&[4I[+X::8G8V$@B<$[%8Z'EXN^S")<*BD+P</"?C]W7,#\<#^
M$.++/#?@'X7_(,[ 3X"@8@#1'&SG!*J00/3,= F(-@0B(\5H?2"Z\0$@8LEN
MQ[T1^'\Y7/J]<EMA'R[.T&>*,I=I)9!8T76L+:3>!K[3N@*TJ;1 E- 72@2.
M #SV??99IDC;/*U665@95=@E0+!0 </WGM0F']\ &@*:ZX_7=2\7S7[J.L_Z
MB2_QU)7BC!?4P=NS#^SJT]F'\^O;\X\6^R#O*LRVK<0^'?[Z[N,OE^S#Y1^W
M?UQ_NCR"@(QE3KW%K@.GP@X_G-U>G/WCE%W]>OGA"&09F:*TOP\VL3_Q[E7B
MW3,8$(N' OZ/H<"_TU  ;*-^(1K;4,D[SX6;037&H<MCP62@[W'D*.3!@X:-
M]IL(GHERS5QQ)WP9CN#WJ/(2G%C?;.PG[Y&0M>J;ST#:2:@6"SYBW!EZ0%27
MP5L?&(Q%1#$\)V(2XG3-BA"=G3Z,; 2/'D86 \]H!,R.P<T !R(>)E=-G*O4
MJ\I+@9J"W41>X'>\[QG?R9DB@8_CN ?_B7D!^X-'0W@_#-5B%Y7SBJ4G:+]A
M$?=<]C=OQ&Z=H12!<+Z@](+@P4?G,-4^N_PJG+$>ZD=T_(2R)B2IL F= (DC
M$>-H!K[L@51'\=CU@"X.$@;&CX./0N'$:CS"RQP8<@#(\R5Q]%PO$D@('HB1
MQ[6TPR-[PD^H#8:@)_0SP,L< ,WU%2,)OZ#H*S$4081C%,B&C&@5\!^9^(IO
MG26Z,^NU1HG7"@K%K425%#(KQP9X?^B#/].32$V0G&,75/<A@C&&P%G4+STB
MN [>+8#7X(WV.5X\^1Y4-;O)@F]E7ARB<0@D!]:+S+E.Y0'& \R.A()1\TA?
MV^/X6BTG8@#CCZ4"L \1'(#N7@((VDCBB"3\I=B?8^5%KN=@*BO29 E3^QHE
M]A7^0).:O[OWH'\7^) ^HE(T 25\.:CQ<#(A_:K%9-%SE&,%GZ@X@)O/(M#!
M?Z&L ;7Q/GCW^S/][LNQDJ&8>W/?4\#F?T]2([4J7C#W1'#E.1"K#ZZZO >!
M@2OTS*((9XP330B1)]DX'DH% B$(&S? QFL0<8B=4**LO*H [\'I3P42#1W(
MROG?+^8$(M5SX#F@3) H_#T(^.0V^.9O'&R:OC]W=?Y).8VJL(\@$ F/'=\#
M9 %=@$<-%!_!4]T[,+;"M5"'[@4\",;-$591C'*#3]"XIM'K :4F5H+'N?=/
MWHT6UKM#F'"&8J1?S,,D)A8!H+&?8EXBO9/;X!&)Y(Z4N//'(]Z;6(#):"?:
MY0%(P9U#@,D0C(@,.(AM'\$7->SP7Y<WO_WST^^W1_JMOH0I^P^3N<([ @='
M#W<[^(EBA^_.;JYOCTC:-_($@$DC_B=*HX,VPO>BH7:LP,L"UB"HH3\&S(5O
M 5+Q.RU!( 1W'L*0MI  3)GYG'AK?3F&J:J4C<'@.(9)L?/+CTF*9<@]& QH
MV6<Y@IGV^QK 1_"J@"$JCX/$QFF> ^"!3&I858(-<%#]L:]E"J_U!8<W@3,0
MZFL47L1[GN_%6MQ!JN4@ $(G3TA$B44."J\.%+P@ #.#2E])78CML?8EA6D7
M:QDS0;"^SP5R*TW-4RT! %P"DW")]WZ1\]ZUIV6#PS8-A',A[_[1?S?*_&G&
M3''X BAL,> !_*N1&L9Y[( K$27(KY48=6>)NWH(]NAHH6FS\)K,^<TIO5:L
M-"Z#;Q)O&6 ;# ,X[W^. ^VC/?*:HKS;I)^1.3T5]JM"_.C!>+^@[FMM=2:A
M(:X13I!&?GW Y<<(O66X="2<(0^\:)2J.P]C+8T(!<.'4'X%HZ>M\CTXS*E!
MT]'H!PFN.;M1B!0P\ILAV. D @%:O1?@:8(DZX=JUS7*?%>-=,DKLG!W.@;P
M];@S^6YJE2OY[(^GC5H$CT2SB^2#]_<P%!MYCI[_HTE#[#562: = E +G!UX
MB2DQ*FP_S>$N$.R9Z#.7M,^R_YK74_3Z  HQZH&I:QUWDTQ*6=814W;\]QP_
M_GLA[UXUH[VKD?SXW5<(WO9G=>U9 CU!W,>F\SP+2K)$3SA9'NLK\.LB[^OC
M0*2>2Z.,0@CA$=]TIJEC5:O5+"Z9M3^+354:^O@^_@R3%;U\SFGRC$#&^< J
M22+D4Q> P/[83;Q,_,-S=:HQNQ["[@$8I+ LRW:[$,US\ P\D (0L,="N;/:
M@><'MS5PV^(8Y+[@V9-"LV#A,[\>]S2V76%0G.:" .$PCSJ%-XN%OO:5(Y&$
MQQ,?H).NI>"EF%#1EU7837(Y]R,YN>=>]"*04(U4C\+GL]L/V>L2=V.]Q<"U
MZJCL1J797+SRM[X+B-6!*AM&R ?B6#OQQ[P?"W7*_7O^$+V9 Z_B(R9Y2D7T
ME"#8YB,8YO^=75Y__!TK@CX)3'D(]P8$_Q>4>_U-#:X]X08Q(V."^0-Z%!$N
M=T875FUA&8&G1L(]9<]-^O$CKP.=LU[_QMEE(U>$0L-JDB=Y_#$N ,RYO2]
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M/7&U14D\O%P?RJ"# ]0" ' %:(;?)^=@#9)V/7 ;=S22YH_APT[S6,.-.T
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M4)54<GU4-) /_6)T4-@ AQ7Q/C:7P,?'$.HHWO-\5#/0C3XZW9CIT6F;*ZU
MJ/6I-ZNA*O^^K+WAU$<%,JFQIVW8U&%.TP)W7@2J/1/%8\\L=?H='\?RS5-+
MEYC8R::N?;*H,I!WJQP@J/$J_YJ#M[M-$- ADS.'3#87'#*Y8V,\,4@O*">+
MK.SKSR>;B04NJP-N'WAH;IIL3&*[6T#1*X7YQLB1%F;//7AHX(%OJ'$(8N0(
M[ U:&-GO>X[VE-DOPOL3-5R[N #$@R'W+'8C)"CZ)"G[2>BFIPZ"6^IN:I\
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MO*!3M6J=[1<BD_$Q0:$HZC$*Q<CV["/7R/9LO FFT:)\VXYY0&<F;/_,Y9Z
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MTG[+'[_""] 6?5*U-:U1Y5\B*D1]C9N\19]715$MO:R15B/M:\<D2C3DBV;
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M>@C=R R0Q<9,J7Y8*;Q'G>6;#>L) 1&6WK8KD56B"5A6]04G4F")L:^72-,
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MZ-&O@,!F[5@A&](?ND=![7ZR"O:5Y\+ Q_S) QM7C(+'-$3;KBL+00.N:*#
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M,C99&>0D3]&A]P:/'AWV8;4<,::'C:LY \^.OCD2(YT# .F"D]G= ^&P18>
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M9*Q.MEK.]OW8HAF(LE<G':/"(15D8FVYT8,$O6^%"]$C0A04+0L._C;ZF^C
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MJU%HSZ&(Z,<S.AM,,Q=<&;Z'\;R-&I!^+/UX&Q0XVF("4]>WTF+SU*P$BBS
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M.J*1 ]YXW9.=T7).I3Q !Z"D/KO'&]Q;NK\XL7HUJN=W7;E1CD>F@UZ*1%F
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MUP1?XPMT6I_>\Y62;-ZL-<Y+>\7LHTVRCTY+0I;&ZF<O%VX?5<Q9Q;&S7K1
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M+?2E)E357<GD,<A2.A=U SRKBT^/1WVD)#"!UP8_* &(9_: E$-%FU9"67;
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MNTQ0FC9 4PPFG']V=A*X5Y!5Y7XZ%;<W;=,Z)C.^I,6BG;%YG8)L4$C**Y,
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MC& PQNB,;,P=\S>%NV!=B<!CW0H2S,<!5*<(P1N)HD0H>=1RZO(A,D(8="I
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M_>7_ %!+ 0(4 Q0    (  E";$]HD)58T00  'X7   1              "
M 0    !F9V5N+3(P,3DQ,3$Q+GAS9%!+ 0(4 Q0    (  E";$]-:H3<(@<
M )=)   5              "  0 %  !F9V5N+3(P,3DQ,3$Q7VQA8BYX;6Q0
M2P$"% ,4    "  )0FQ/G#'Q&?D$  #<*P  %0              @ %5#
M9F=E;BTR,#$Y,3$Q,5]P<F4N>&UL4$L! A0#%     @ "4)L3U/9A(H4$P
M*;D  !0              ( !@1$  &9G96XM.&M?,C Q.3$Q,3$N:'1M4$L!
M A0#%     @ "4)L3R8:V1;K.   &I0% !               ( !QR0  &9G
M96XM97@Y.3%?-BYH=&U02P$"% ,4    "  )0FQ/B_+*0D-2  !SQ0$ $@
M            @ '@70  9F=E;BUE>#DY,E\Q-#(N:'1M4$L%!@     &  8
*A0$  %.P      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>fgen-8k_20191111_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="fgen-20191111.xsd" xlink:type="simple"/>
    <context id="C_0000921299_20191111_20191111">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
        </entity>
        <period>
            <startDate>2019-11-11</startDate>
            <endDate>2019-11-11</endDate>
        </period>
    </context>
    <dei:AmendmentFlag contextRef="C_0000921299_20191111_20191111" id="F_000001">false</dei:AmendmentFlag>
    <dei:EntityRegistrantName contextRef="C_0000921299_20191111_20191111" id="F_000003">FIBROGEN INC</dei:EntityRegistrantName>
    <dei:EntityCentralIndexKey contextRef="C_0000921299_20191111_20191111" id="F_000004">0000921299</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="C_0000921299_20191111_20191111" id="F_000000">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="C_0000921299_20191111_20191111" id="F_000002">2019-11-11</dei:DocumentPeriodEndDate>
    <dei:EntityIncorporationStateCountryCode contextRef="C_0000921299_20191111_20191111" id="F_000007">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="C_0000921299_20191111_20191111" id="F_000006">001-36740</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="C_0000921299_20191111_20191111" id="F_000008">77-0357827</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="C_0000921299_20191111_20191111" id="F_000009">409 Illinois Street</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="C_0000921299_20191111_20191111" id="F_000010">San Francisco</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="C_0000921299_20191111_20191111" id="F_000011">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="C_0000921299_20191111_20191111" id="F_000012">94158</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="C_0000921299_20191111_20191111" id="F_000013">415</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="C_0000921299_20191111_20191111" id="F_000014">978-1200</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="C_0000921299_20191111_20191111" id="F_000015">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="C_0000921299_20191111_20191111" id="F_000016">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="C_0000921299_20191111_20191111" id="F_000017">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="C_0000921299_20191111_20191111" id="F_000018">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="C_0000921299_20191111_20191111" id="F_000019">Common Stock, $0.01 par value</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="C_0000921299_20191111_20191111" id="F_000020">FGEN</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="C_0000921299_20191111_20191111" id="F_000021">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="C_0000921299_20191111_20191111" id="F_000005">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
